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ABSTRACT 
 
Role of Ataxia Telangiectasia Mutated Kinase in the Healing Process of the Heart  
Following Myocardial Infarction  
by 
Laura Lynn Daniel 
Ataxia telangiectasia (AT), caused by mutations in the gene encoding ataxia telangiectasia 
mutated kinase (ATM), is a rare autosomal recessive disorder.  AT individuals exhibit neuronal 
degeneration and are predisposed to cancer. Carriers of this disorder are predisposed to cancer 
and ischemic heart disease. Heart disease, mostly due to myocardial infarction (MI), is a leading 
cause of death in the US.  Following MI, release of catecholamines in the heart stimulates β-
adrenergic receptors (β-AR). Our lab has shown that β-AR stimulation increases ATM 
expression in the heart and myocytes, and ATM plays an important role in β-AR-stimulated 
myocardial remodeling with effects on function, fibrosis and apoptosis. Using wild-type (WT) 
and ATM heterozygous knockout (hKO) mice, this study investigated the role of ATM in the 
inflammatory, proliferative and maturation phases of infarct healing post-MI.  During the 
inflammatory phase, 1 and 3 days post-MI, a deficiency of ATM resulted in decreased left 
ventricular dilation as measured by echocardiography.  It decreased the number of neutrophils 
and macrophages in the heart 1 day post-MI.  Myocardial fibrosis, expression of alpha-smooth 
muscle actin (α-sma) and apoptosis were higher in the infarct region of ATM deficient hearts. 
Akt activation (anti-apoptotic) was lower, while Bax expression (pro-apoptotic) was higher in 
the infarct region of ATM deficient hearts. During the proliferative phase, 7 days post-MI, ATM 
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deficiency attenuated cardiac dysfunction as measured by echocardiography.  ATM deficient 
hearts exhibited increased fibrosis and expression of α-sma in the infarct region with increased 
myocyte apoptosis in the border area. During the maturation phase, 14 and 28 days post-MI, 
ATM deficiency resulted in exaggerated cardiac function. It associated with increased fibrosis, 
expression of α-sma and decreased cardiac cell apoptosis in the infarct region 28 days post-MI. 
Myocyte hypertrophy was greater in the non-infarct region during ATM deficiency. ATM 
deficiency decreased expression of p16 (marker of cell senescence) and activation of pro-
apoptotic protein, GSK-3β.  Thus, ATM modulates the remodeling processes of the heart 
including function, fibrosis, apoptosis and hypertrophy post-MI. ATM (1) delays the 
inflammatory response post-MI, (2) decreases dilative remodeling during inflammatory and 
proliferative phases and (3) exaggerates dysfunction during the maturation phase.  
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CHAPTER 1 
INTRODUCTION 
Heart Disease and Myocardial Infarction 
According to the Global Burden of Disease Study 2010, heart disease is one of the 
leading causes of death worldwide (Lozano et al. 2012).  It is currently considered the leading 
cause of death in the US.  An estimated 83.6 million American adults have had at least one type 
of cardiovascular disease; this includes high blood pressure, myocardial infarction, stroke and 
heart failure. It is estimated that the direct and indirect (loss of productivity) cost of 
cardiovascular diseases is in upwards of $300 billion per year. It is projected that by 2030 the 
costs will rise to over $900 billion (Go et al. 2014).  Myocardial infarction (MI) is a large 
contributor to this burden. In 2006, it was estimated that MI occurs in approximately 865,000 
people annually, and is responsible for nearly half of all deaths due to cardiovascular diseases 
(Turpie 2006). 
MI and Cardiac Myocyte Death 
Cardiac myocytes are responsible for the contractile function of the heart.  MI is an 
ischemic event that leads to death of cardiac myocytes resulting in a decline in cardiac function 
(Alpert et al. 2000).  Cardiac myocyte death occurs via apoptosis and necrosis (Fliss and 
Gattinger 1996; James 1998). Myocytes are terminally differentiated and have limited 
regenerative capacity (Frangogiannis 2008). Following extensive myocyte loss, such as is the 
case during MI, the remaining myocytes usually aren’t adequate enough to maintain cardiac 
function which leads to cardiac dysfunction and, then, heart failure. Therefore, the extent of 
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myocyte death can be used as a predictor of heart failure (Olivetti et al. 1997; Nakayama et al. 
2007).  
Apoptosis is a controlled cell death that can occur in response to irreparable DNA 
damage. During apoptosis there is chromatin condensation, cellular shrinkage and cellular 
fragmentation into apoptotic bodies (Ouyang et al. 2012). These apoptotic bodies are surrounded 
by a plasma membrane in order to prevent the release of the intracellular contents (Krysko et al. 
2006). This process minimizes the inflammatory response and damage to the surrounding tissue 
(Ouyang et al. 2012).  Following MI, there is an increase in sympathetic nerve activity caused by 
an increase in catecholamines (Schömig 1990). Accumulation of catecholamines is suggested as 
a contributing factor leading to heart failure (Downing and Chen 1985).  This is in part due to the 
fact that catecholamines are shown to induce cardiac myocyte apoptosis, both in vitro and in vivo 
(Shizukuda et al. 1998; Colucci et al. 2000; Singh et al. 2001). Specific β1-adgernergic receptor 
(β1-AR) blockers such as metoprolol and non-specific β-AR-blockers such as carvedilol have 
been shown to decrease myocyte apoptosis (Kawai et al. 2004; Ahmet et al. 2008).   
Necrosis was originally thought to be “accidental" cell death that was uncontrolled. Since 
then, mediators of necrotic death such as receptor-interacting protein kinases (RIP) and poly 
(ADP ribose) polymerase (PARP) have been discovered and the idea that necrosis is another 
form of programmed cell death, like apoptosis, has been gaining acceptance. Increased oxidative 
stress due to MI can induce myocyte necrosis. Necrosis associates with loss of membrane 
integrity resulting in the intracellular material being released into the extracellular space (Ouyang 
et al. 2012). Loss of membrane integrity is a result of cellular swelling.  On the other hand, 
apoptosis results in cell shrinkage followed by complete engulfment of the apoptotic cell by 
phagocytes. The necrotic cellular contents are internalized by a macropinocytotic mechanism. 
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During this process only parts of the cell are taken up by phagocytes (Krysko et al. 2006). The 
cellular contents that remain in the extracellular environment are thought to act as “danger 
signals” and elicit an inflammatory response (Proskuryakov et al. 2003). However, this idea is 
controversial since studies have shown that exposure of necrotic cells, like apoptotic cells, to 
macrophages is not sufficient to alter macrophage expression of pro-inflammatory cytokines 
(Cocco and Ucker 2001; Brouckaert et al. 2004).  Necrotic cells, but not apoptotic cells, trigger 
an increase in the secretion of pro-inflammatory cytokines from independently-activated 
macrophages (Cocco and Ucker 2001).  It is possible that release of cytokines or other factors 
from necrotic cells also may be critical for the induction of an inflammatory response. Cells that 
die as a result of necrosis, but not apoptosis, upregulate and secrete the pro-inflammatory 
cytokine interleukin-6 (IL-6) (Vanden Berghe et al. 2006).  
Infarct Healing Post-MI 
Since the heart has limited regenerative capacity, the damaged heart is repaired and replaced by a 
collagen-based scar.  The repair process induces structural and functional changes in the infarct 
as well as non-infarct regions of the heart.  This cardiac remodeling process associates with left 
ventricle (LV) chamber dilation, myocyte hypertrophy and formation of an infarct scar. The 
infarct healing or reparative process can be divided into these overlapping phases: (a) 
Inflammatory; (b) Proliferative and (c) Maturation (Frangogiannis 2008). 
Inflammatory Phase. Inflammation following MI is activated by a number of pathways. 
As a result of necrosis, the complement cascade can be activated (Pinckard et al. 1975). This 
leads to leukocyte recruitment (Hill and Ward 1971). There is also an increase in “damage 
associated molecular patterns” (DAMPs). DAMPs act as signaling molecules further activating 
the innate inflammatory response.  These signaling molecules can be released by necrotic cells. 
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Damaged extracellular matrix proteins are also considered to be DAMPs.  Other examples of 
DAMPs include heat shock protein (HSPs), high-mobility group box-1 (HMGB1), low 
molecular weight hyaluronic acid and fibronectin fragments (Timmers et al. 2012). Activation of 
the innate immune response via DAMPs is in part due to the activation of toll like receptors 
(TLR-2 and -4) (Termeer et al. 2002; Jiang et al. 2005).  
Following MI, the generation of oxygen-related free radicals exceeds the heart’s capacity 
for removal, resulting in increases in reactive oxygen species (ROS).  This increase in ROS can 
cause impairments in mitochondrial function by increasing lipid peroxidation, enhancing 
mitochondrial DNA damage as well as inducing inactivation of the electron transport chain 
(ETC) proteins and antioxidant enzymes (Chen and Zweier 2014). An increase in ROS also can 
trigger an inflammatory response which is in part due to the fact that oxidative stress activates 
NF-κB (Kabe et al. 2005). NF-κB is a transcription factor that regulates gene expression 
involved in the inflammatory response, cell adhesion, growth control and cell death. NF-κB can 
be activated by a variety of other stimuli including cytokines such as tumor necrosis factor-α  
(TNF-α) and interleukin-1β (IL-1β) (Stancovski and Baltimore 1997). 
During the inflammatory phase, chemokines, cytokines and adhesion molecules are 
upregulated leading to the recruitment of leukocytes into the wound with neutrophils being 
among the first (Frangogiannis 2008). The inflammatory phase in humans usually begins 6 hours 
after infarction and can last up to 4 days (Cleutjens, Blankesteijn, Daemen, & Smits, 1999), 
whereas, in rodents the inflammatory response last approximately 1-48 hours post-MI 
(Dobaczewski et al. 2010). The increase in pro-inflammatory cytokines and chemokines results 
in the activation of endothelial cells thus priming them to “capture” neutrophils. The adherence 
of neutrophils to the endothelium of post capillary venules is mediated by members of the 
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selectin family. The L-selectins of neutrophils bind to P and/or E selectin in the endothelials. 
This attachment triggers activation of integrins via a G protein-coupled receptor (GPCR). The 
integrin responsible for this attachment is β2-integrin which is expressed exclusively on cells of 
leukocyte origin. β2-integrins can attach to intercellular adhesion molecules (ICAM-1) expressed 
in the endothelium. This results in a transition from leukocyte rolling (via selectins) to firm 
adhesion. Following this, leukocytes transmigrate into the infarct region through interactions that 
involve a wide variety of adherent molecules including platelet endothelial cell adhesion 
molecule (PECAM)-1, ICAM-1, vascular-endothelial (VE)-cadherin and members of the 
junctional adhesion molecule (JAM) family. This occurs both at endothelial cell junctions and at 
non-junctional locations (Williams et al. 2011).  
Following neutrophil recruitment, there is an infiltration of monocytes and lymphocytes 
into the wound.  Monocytes eventually differentiate into macrophages in part due to the 
upregulation of macrophage-colony stimulating factor (MCSF). MCSF appears to be important 
for the survival of macrophages since its upregulation associates with macrophage proliferation 
(Frangogiannis et al. 2003). Macrophages appear in the infarcted heart two days post-MI to aid 
in clearing the wound of dead cells, including neutrophils, and matrix debris (Matsui et al. 2010). 
They release anti-inflammatory cytokines and growth factors which aid in formation of highly-
vascularized granulation tissue. In addition, the release of cytokines and growth factors results in 
the suppression of pro-inflammatory mediators and the proliferation of fibroblasts and 
endothelial cells. Macrophages also aid in wound repair by secreting matrix metalloproteinases 
(MMPs) as well as their inhibitors (Frangogiannis 2008).  
 The extracellular matrix (ECM) is an important structural component of the myocardium 
with the majority of structural integrity coming from type I and III fibrillar collagen. The ECM 
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provides support for myocytes and blood vessels, helps maintain cardiac shape, and aids in 
coordinating the delivery of force that is generated by myocytes to the ventricular chamber. The 
ECM is an important determinate of diastolic and systolic myocardial stiffness.  Alterations in 
ECM organization can result in changes to cardiac function (Weber 1989). MMPs are proteins 
that can degrade the ECM. Following MI, there is an initial increase in ECM degradation. Type I 
collagen fragments can be found in the serum of pigs 15-30 minutes after coronary artery 
occlusion (Villarreal et al. 2004). The initial increase in cardiac ECM degradation comes from 
activation of latent MMPs as opposed to production of new MMPs (Etoh et al. 2001). Increased 
degradation of the ECM post-MI is thought to be responsible for myocyte slippage, sarcomere 
overdistension, wall thinning and cardiac rupture following MI (Cleutjens, Kandala, et al. 1995). 
Following degradation of the original matrix, there is a formation of fibrin-based provisional 
matrix. This provisional matrix can serve as a scaffold for the migration and proliferation of 
inflammatory cells, endothelial cells and fibroblasts. However, this provisional matrix is lysed by 
proteolytic enzymes that are produced by granulation tissue cells as the wound heals. A cell-
derived matrix containing cellular fibronectin and hyaluronan replaces the provisional matrix. 
Cellular fibronectin is secreted by fibroblasts and macrophages (Dobaczewski et al. 2010).  
Proliferative Phase. Following the inflammatory phase of wound healing is the 
proliferative phase. During this phase, there is a suppression of the inflammatory response by 
“stop signals” such as IL-10 and transforming growth factor (TGF)-β1 as well as an increase in 
proliferation of myofibroblasts and endothelial cells.  In rodents, the proliferative phase begins 
approximately 48 hours post-MI and lasts up to 5 days post-MI (Dobaczewski et al. 2010).  In 
higher mammals, the proliferative phase begins 7 days post-MI and can last up to 14 days post-
MI (Cleutjens et al. 1999; Virag and Murry 2003). 
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Myofibroblasts are not generally found in the healthy heart.  However, they are present in 
the infarct region following MI and play an important role in wound healing.  Myofibroblasts aid 
in wound closure and are the main source of collagen production during infarct healing 
(Cleutjens, Verluyten, et al. 1995). Myofibroblasts isolated from infarct regions exhibit a higher 
rate of proliferation and collagen synthesis when compared to fibroblasts isolated from non-
infarct regions or sham operated hearts. Interestingly, the myofibroblasts exhibited a decrease in 
migration that was attributed to increased adhesion to some the ECM proteins (Squires et al. 
2005). Myofibroblasts can come from a variety of sources such as epithelial cells, endothelial 
cells, mesenchymal stem cells, bone marrow-derived circulating progenitor cells, smooth muscle 
cells and pericytes (Turner and Porter 2013). Resident fibroblasts are transformed into 
myofibroblasts in a two-step process. During the first step, fibroblasts respond to increased 
mechanical tension and transform into proto-myofibroblasts which are characterized by the 
formation of stress fibers containing β- and γ-cytoplasmic actins. During the second step, the 
proto-myofibroblasts are exposed to additional signals such as active TGF-β and ED-A (a splice 
variant of cellular fibronectin) resulting in their conversion into myofibroblasts (Serini et al. 
1998; Hinz et al. 2001; Tomasek et al. 2002). Normally TGF-β requires proteolytic cleavage to 
become active, but it has been shown that mechanical strain can result in TGF-β activation in the 
absence of protease activity (Buscemi et al. 2011).  Once the proto-myofibroblast express α-sma 
they are referred to as myofibroblasts.  The acquisition of α-sma is thought to aid in the 
contraction of the heart following injury (Dobaczewski et al. 2010).  
Following MI, there is an increase in collagen production with type I and type III 
procollagen increasing several fold in the infarct region. Type III procollagen mRNA levels have 
been shown to increase in the infarct region as early as 2 days post-MI and can remain elevated 
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for up to 21 days post-MI, while type I procollagen increased in the infarct region 4 days post-MI 
and remained elevated up to 90 days post-MI. While most of the increases in collagen production 
occur in the infarct region, there can also be an increase in collagen production in the non-infarct 
region of the right ventricle as well as the non-infarcted septum.  However, the increase in 
collagen production in the non-infarct region is less than that seen in the infarcted LV region. 
When examining the phenotype of the cells responsible for collagen production, it appears that 
the collagen being produced in the infarcted  region comes from myofibroblasts, while the 
collagen produced in the non-infarcted region originates from non-transformed fibroblasts 
(Cleutjens, Verluyten, et al. 1995).  
Part of the wound healing process is the formation of a new vasculature. Fibroblasts 
move into the wound in order to create a matrix necessary for structural support.  There is also 
growth of new blood vessels, in the infarct region, which provides the area with oxygen and 
nutrients (Tonnesen et al. 2000). Angiogenesis is a process in which new microvessels are 
formed from pre-existing capillaries. Endothelial cells become activated in response to a variety 
of signals such as hypoxia, growth factors and nitric oxide. Once activated, the endothelial cells 
begin to proliferate forming a new vessel lumen which is later covered by mural cells to ensure 
neovessel stability (Cochain et al. 2013).    
Maturation Phase. In humans, the maturation phase usually begins 2-3 weeks post-MI 
and can last for several months (Cleutjens et al. 1999).  While, in rodents the maturation phase 
occurs from approximately day 14 until 2 months post-MI (Dobaczewski et al. 2010).  During 
the maturation phase of healing, fibroblasts and vascular cells undergo apoptosis (Frangogiannis 
2008). Cross-linking of the collagen matrix is carried out by enzymes such as lysyl-oxidase 
which imparts tensile strength to the matrix (Eyre 1980). However, cross-linking also leads to 
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increases in passive stiffness resulting in diastolic dysfunction (Kato et al. 1995; Badenhorst et 
al. 2003).  
During the maturation phase, there is a decrease in myofibroblast density in the newly-
formed scar. In humans, myofibroblasts can persist for years.  The reduction in myofibroblasts is 
thought to occur as a combination of myofibroblast senescence and apoptosis. (Turner and Porter 
2013). While short-term inhibition of myofibroblast apoptosis may be beneficial early post-MI, 
the persistence presence of myofibroblasts usually results in excessive scaring leading to 
ventricular wall stiffening and cardiac dysfunction (Brown et al. 2005).  
Ataxia Telangiectasia.  
Ataxia telangiectasia (AT) is a rare autosomal recessive disorder caused by mutations in 
the gene encoding for ataxia telangiectasia mutated kinase (ATM).  It affects approximately 
1:40,000 – 1:300,000 children (Sandoval et al. 1999).  Although, mutations in the ATM gene that 
result in AT are varied and do not occur at a particular location within the gene, the mutations 
generally lead to protein instability and lack of a functional protein (McKinnon 2004). On the 
other hand, some mutations result in decreased amounts of the functional protein or cause a 
decrease in its kinase activity. These mutations result in a less severe phenotype than do the 
mutations that cause the complete absence of a functional protein (Stewart et al. 2001). The most 
notable sign of AT is loss of cerebella function, progressive dysarthria and choreoathetosis 
(McKinnon 2004). MRI scans show that there is cerebellar atrophy with involvement of the 
vermis (Farina et al. 1994; Tavani et al. 2003). Affected individuals usually have ataxia of the 
limbs at a very early age resulting from neuronal degeneration causing them to be wheelchair 
bound prior to adolescence. As AT individuals age, there is an increased risk of aspiration 
(Lefton-Greif et al. 2000). These individuals also suffer from thymic degeneration, immune 
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deficiency, retarded somatic growth, premature aging, telangiectasia of the eyes and skin, 
gonadal dysgenesis and sensitivity to ionizing radiation (Rotman 1998).  The 
immunodeficiencies usually present in the form of decreased Ig subtypes and lymphopenia. 
Upper and lower respiratory tract infections are frequent, although it should be pointed out that 
systemic bacterial, severe viral and opportunistic infections are rare (Nowak-Wegrzyn et al. 
2004). There is also a cancer predisposition that usually presents in the form of leukemia or 
lymphoma (Gumy-Pause et al. 2004). 
 Carriers of a mutated Atm allele make up approximately 1.4-2.0% of the general 
population. One functional copy of the gene coding for ATM is able to compensate to a large 
extent for the missing gene; however, individuals with only one copy do exhibit some 
abnormalities. Carriers of a mutated allele have a significantly increased risk of death when 
compared to non-carriers. On average, these individuals die 7 to 8 years earlier than non-carriers 
with cancer being the predominant cause followed by ischemic heart disease as the second major 
cause of death resulting in premature death approximately 11 years earlier than the non-carriers 
(Su and Swift 2000).  Carriers also exhibit increased susceptibility to metabolic diseases such as 
hypertension, diabetes and impaired glucose metabolism (Stracker et al. 2013).  
ATM, DNA repair and oxidative stress 
ATM is a large serine-threonine protein kinase with a molecular weight of approximately 
350 kDa. It contains 66 exons and its mRNA length is approximately 12 kb. The most widely 
known cellular function of ATM is to aid the in repair of DNA double-stranded breaks (DSB). 
These breaks can occur as a result of meiosis, immune system maturation, and telomere 
maintenance (McKinnon 2004). Following DSB, ATM initiates the repair process beginning 
with autophosphorylation, which results in ATM activation (Bakkenist and Kastan 2003). 
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Inactive ATM exists as a dimer. ATM autophosphorylates several residues following DNA 
damage, including S367, S1893, S1981 and S2996, which results in its activation.  This 
activation of ATM is MRN complex (MRE11–RAD50–NBS1) dependent, and results in ATM 
becoming a monomer and beginning its kinase activity (Bakkenist and Kastan 2003; Kozlov et 
al. 2006; Kozlov et al. 2011).  In response to DNA damage, activation of ATM can induce cell 
cycle arrest during G1/S, G2/M, and S phases in order to prevent replication of the damaged 
DNA.  (Rotman 1998).  ATM can activate and stabilize p53, a regulator of the G1/S checkpoint 
and in some cases is an initiator of apoptosis. ATM accomplishes this not only by directly 
phosphorylating p53, but also by phosphorylating Chk2 kinase and Mdm2. Chk2 phosphorylates 
p53 at a site different from ATM also resulting in its activation. Phosphorylation of Mdm2, on 
the other hand, inhibits Mdm2 from signaling for the degradation of p53 (Barzilai et al. 2002).  
ATM can also phosphorylate BRCA1, resulting in cell cycle arrest at intra-S-phase and G2-M 
check points. Besides phosphorylating cell cycle arrest proteins, ATM also phosphorylates a 
variety of proteins that result in DNA repair. Among them are proteins in the MRN complex. 
Following DNA damage the MRN complex rapidly forms foci at the site of DNA damage in 
order to repair the damaged DNA (Rotman 1998). The MRN complex is the primary sensor of 
DSB and ATM’s recruitment to this complex appears necessary for full activation of ATM 
(Berkovich et al. 2007). 
While ATM does take part in DNA repair, there is a built-in redundancy within the cell. 
DNA-dependent protein kinases (DNA-PKs) also respond to DSB. In fact, ATM responds to 
only approximately 10% of DSB, most of which are in regions of heterochromatin. ATM and 
DNA-PK  redundancy may explain the fact the global DSB repair capability of ATM deficient 
cells is only partially attenuated (Goodarzi et al. 2008). However, AT patients still have a 
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hypersensitivity to radiation and are predisposed to cancer. While there are no gross 
abnormalities in either recombination or V(D)J rearrangements, AT individuals are often 
immunocompromised (Lavin et al. 2007).  
ATM is predominantly located in the nucleus and is activated in response to DNA 
damage. However, ATM also has a presence and function in the cytoplasm that is unrelated to 
DNA damage (Shiloh and Ziv 2013).  ATM that is activated in response to oxidative stress can 
exist as a dimer and is MRN independent (Guo et al. 2010). ATM may play a part in redox 
balance by regulation of an important antioxidant cofactor, NADH. ATM is shown to enhance 
the pentose phosphate pathway (PPP), a major source of NADH, in response to genotoxic stress.  
This is accomplished by inducing glucose-6-phosphate dehydrogenase (G6PD) activity, the rate 
limiting enzyme in the PPP (Cosentino et al. 2011).  Increasing autophagy also provides a 
protective mechanism against ROS. ATM can enhance autophagy by phosphorylating tuberous 
sclerosis complex 2 (TSC2), a negative regulator of mammalian target of rapamycin (mTORC1), 
which removes the repression of autophagy by mTORC1 (Shiloh and Ziv 2013).  
Lack of ATM is suggested to result in increased levels of ROS and signs of oxidative 
stress. ATM knockout (KO) mice have differing levels of activity of thioredoxin, catalase and 
manganese superoxide dismutase (SOD).  Alterations in these compounds are thought to keep 
neurons at an increased state of oxidative stress causing the neuronal degeneration seen in AT 
patients (Kamsler et al. 2001). The increased levels of ROS in the brain appear to be located in 
the cerebellum and striatum, but not in the cortex (Quick and Dugan 2001). In addition to AT 
cells having increased levels of ROS, fibroblast isolated from AT patients have increased 
susceptibility to oxidative stress when compared with fibroblasts from non-affected individuals 
(Yi et al. 1990; Ward et al. 1994).  Mitochondria are major sites of ROS production (Cadenas 
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and Davies 2000).  ATM KO mice exhibit mitochondrial dysfunction in thymocytes; there is an 
increase in mitochondrial size as well as mitochondrial ROS production. The increase in 
mitochondria size is thought to be due to a decrease in mitochondrial mitophagy as opposed to an 
increase in mitochondrial biogenesis (Valentin-Vega et al. 2012). 
ATM and the heart 
As discussed previously, increases in sympathetic nerve activity are a major factor post-
MI.  Increases in sympathetic activity result in an accumulation of catecholamines, such as 
norepinephrine, in the interstitial space.  Stimulation of β-AR in response to norepinephrine 
induces cardiac myocyte apoptosis in vivo and in vitro (Shizukuda et al. 1998; Colucci et al. 
2000; Singh et al. 2001). A major project in our lab investigates the molecular signals involved 
in cardiac myocyte apoptosis in response to β-AR stimulation. To identify differential expression 
of apoptosis-related genes in response to β-AR stimulation our lab used a Gene-Array technique.  
For this, mice were infused with isoproterenol (a β-AR agonist) for 7 days.  Total RNA, isolated 
from the LV, was reverse-transcribed and radio-labeled.  The resultant cDNAs, from vehicle-
infused and isoproterenol-infused heart, were simultaneously hybridized with two Gene-Array 
membranes containing 96 apoptosis-related genes. This analysis revealed increased expression of 
ATM in the hearts in response to β-AR stimulation.  RT-PCR confirmed increased expression of 
ATM in the heart and in adult cardiac myocytes (Foster et al. 2011).  To investigate the role of 
ATM in myocyte apoptosis and myocardial remodeling, our lab used ATM heterozygous 
knockout (hKO) mice.  Homozygous knockout (KO) mice are infertile and they die around the 
age of 2 months due to thymic lymphomas.  Therefore, we breed hKO mice which provides us 
with KO mice.  We found that at basal levels body weights (BW) and heart weights (HW) are 
lower in KO mice when compared to the age-matched wild-type (WT) mice.  However, there 
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was no difference in HW/BW ratio, an indicating no cardiac hypertrophy.  KO mice also 
exhibited increased myocardial fibrosis and myocyte hypertrophy.  Measurement of structural 
and functional parameters of the heart using echocardiography showed that while the KO hearts 
did not display differences in percent fractional shortening (%FS) or ejection fraction (EF) they 
did have reduced septal wall thickness and LV cavity diameter.  Expression of fibrosis-related 
genes (connective tissue growth factor, CTGF; plasminogen activator inhibitor, PAI-1; and 
MMP-2) and hypertrophy-related genes (atrial natriuretic peptide, ANP) were higher in KO 
hearts.  Using WT and ATM KO mice, we examined the role of ATM in cardiac remodeling 
following 24 hours of β-AR stimulation using isoproterenol.  β-AR stimulation resulted in an 
increase in myocyte size in both genotypes with no significant differences between the two 
genotypes.  Apoptosis was increased in both genotypes following β-AR stimulation, with no 
differences in apoptosis between the two genotypes. Interestingly, β-AR stimulation resulted in 
distinct differences in the activation of apoptosis-related proteins, when comparing the two 
genotypes.  Phosphorylation of p53 and activation of JNKs were absent in KO hearts, but present 
in WT hearts.  In addition, Akt activation was also lower in KO hearts when compared to WT 
hearts.  These results led us to suggest that β-AR-stimulated apoptosis in the WT hearts was a 
result of p53- and JNKs-dependent mechanisms, while decreased Akt activity appears to play a 
role in increased myocyte apoptosis in the absence of ATM (Foster et al. 2012). 
Using WT and hKO mice our lab also examined the effects of ATM deficiency in cardiac 
myocyte apoptosis and cardiac remodeling following 28 days of β-AR stimulation. In this study, 
β-AR stimulation increased the functional parameters of the heart as analyzed by increased %FS 
and EF; however, the increase in %FS and EF was blunted in ATM deficient hearts. β-AR 
stimulation resulted in a significant increase in fibrosis as well as apoptosis in both groups 
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although the increase in fibrosis and myocyte apoptosis was higher in ATM deficient hearts. β-
AR stimulation increased phosphorylation of p53 and expression of p53 and Bax to a similar 
extent in both groups; however, there was a differential expression of fibrosis-related proteins; 
e.g. MMPs, TIMP-2, and β1- integrins.  These studies suggested a protective role for ATM in 
myocardial remodeling following β-AR stimulation (Foster et al. 2011). 
Specific Aims  
 The overall goal of this project was to understand the role of ATM in cardiac myocyte 
apoptosis and myocardial remodeling following MI. Based on the observations in our β-AR 
stimulation model, we hypothesized that ATM deficiency would affect cardiac remodeling 
following MI, specifically with regard to apoptosis, fibrosis and function, early and late post-MI.  
As discussed previously, the myocardial remodeling (infarct healing) process can be divided into 
three overlapping phases: inflammatory, proliferative and maturation. The overall goal of this 
project was to examine how ATM deficiency affects each stage of the infarct healing process. 
The specific aims of this study were: (1) investigate how ATM deficiency affects cardiac 
remodeling during the inflammatory phase using 1 and 3 days post-MI time points; (2) examine 
how ATM deficiency alters cardiac remodeling during the proliferative phase of infarct healing 
using a 7 day post-MI time point and (3) determine how ATM deficiency alters the maturation 
phase of the infarct healing using a 28 days post-MI time point. 
.  
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Abstract 
Background: Ataxia-telangiectasia results from mutations in Ataxia Telangiectasia Mutated 
Kinase (ATM) gene. We recently reported that ATM deficiency attenuates left ventricular (LV) 
dysfunction and dilatation 7 days after myocardial infarction (MI) with increased apoptosis and 
fibrosis. Here we investigated the role of ATM in the induction of inflammatory response, and 
activation of survival signaling molecules in the heart acute post-MI.  Methods and Results: LV 
structure, function, inflammatory response and biochemical parameters were measured in wild-
type (WT) and ATM heterozygous knockout (hKO) mice 1 and 3 days post-MI. ATM deficiency 
had no effect on infarct size. MI-induced decline in heart function, as measured by changes in % 
fractional shortening, ejection fraction and LV end systolic and diastolic volumes, was lower in 
hKO-MI versus WT-MI (n=10-12). The number of neutrophils and macrophages was 
significantly lower in the infarct LV region of hKO versus WT 1 day post-MI.  Fibrosis and 
expression of α-smooth muscle actin (myofibroblast marker) were higher in hKO-MI, while 
active TGF-β1 levels were higher in the WT-MI 3 days post-MI. Myocyte cross-sectional area 
was higher in hKO-sham with no difference between the two MI groups. MMP-9 protein levels 
were similarly increased in the infarct LV region of both MI groups. Apoptosis was significantly 
higher in the infarct LV region of hKO at both time points. Akt activation was lower, while Bax 
expression was higher in hKO-MI infarct. Conclusion: ATM deficiency results in decreased 
dilative remodeling and delays inflammatory response acute post-MI. However, it associates 
with increased fibrosis and apoptosis.   
 
Keywords: ATM, apoptosis, cardiac remodeling, fibrosis, myocardial infarction, inflammation 
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Introduction 
Ataxia–telangiectasia (A-T) is a rare autosomal recessive genetic disorder that causes 
neurological degeneration. It is caused by mutations in the gene encoding for ataxia 
telangiectasia mutated kinase (ATM) 1. This disease affects approximately 1 in 40,000 births in 
the US 2. A-T individuals are predisposed to the development of cancer, usually lymphoid 
cancer. In addition, these individuals suffer from immunological problems resulting in frequent 
sino-pulmonary infections 2. Both humoral and cell-mediated immunity are affected, the later 
showing itself in the form of lymphopenia 3.  Individuals that are recessive for this mutation 
usually die 7 to 8 years earlier than non-carrier as a result of either cancer or ischemic heart 
disease 4.  
ATM, a ~370 kDa protein kinase, is a member of the phosphatidylinositol 3-kinase-like protein 
kinase (PIKK) family. Genotoxic stress, oxidative stress and growth factors affect ATM gene 
expression in various cell types 5;6. ATM is activated in response to DNA double-strand breaks 
caused by ionizing radiation and V(D)J recombination in B and T lymphocyte development 3. It 
is also shown to be activated in cells exposed to hypoxia, insulin, and reactive oxygen species 
independent of DNA damage. ATM activation affects cell cycle check points, apoptotic 
signaling, senescence, and DNA repair 7.  
Myocardial infarction (MI) induces cardiac cell death due to apoptosis and necrosis, thereby 
initiating the inflammatory process. Neutrophils are the first inflammatory cells recruited to the 
infarct area 8. Infiltration of neutrophils occurs within hours and peaks 1-3 days post-MI 9. 
Neutrophils facilitate the post-MI repair process by phagocytosing dead cells and tissue debris 8. 
During the inflammatory process cytokines such as TNF-α, IL-1β, and IL-6 are induced 10;11. 
Neutrophils then undergo apoptosis generating annexin A1 and lactoferrin which inhibits 
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neutrophil recruitment and attracts phagocytic macrophages to remove neutrophils. Once the 
macrophages have engulfed the neutrophils, they activate the anti-inflammatory pathway by 
producing molecules such as IL-10 and TGF-β marking the end of the inflammatory phase of 
infarct healing and the beginning of the proliferative phase of healing 12. During the proliferative 
phase, activated fibroblast (myofibroblast) produce extracellular matrix proteins aiding in the 
scar formation 8. Our previous work examined the role of ATM in myocardial remodeling post-
MI during the proliferative phase of infarct healing. We reported that ATM deficiency attenuates 
LV dysfunction and dilatation 7 days post-MI. In addition, we provided evidence that ATM 
deficiency results in increased cardiac fibrosis and expression of α-smooth muscle actin (α-SMA, 
a marker for myofibroblasts) in the infarct region 7 days post-MI 13.  The objective of this study 
was to investigate the role of ATM deficiency in cardiac remodeling during the inflammatory 
phase of infarct healing. A major finding of this study is that deficiency of ATM associates with 
decreased inflammatory response and dilative remodeling early post-MI without affecting infarct 
size. ATM deficiency also affects apoptosis, fibrosis, expression of proteins involved in fibrosis 
and inflammation, and activation of apoptosis-related kinases. 
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Methods 
Vertebrate Animals 
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All of the 
experiments were performed in accordance with the protocols approved by the East Tennessee 
State University Animal Care and Use Committee. ATM transgenic mice (129xblack Swiss 
hybrid background) were purchased from Jackson Laboratory. Aged-matched (~4 month old) 
male and female mice were used for the study. The study used heterozygous knockout (hKO) 
mice since homozygous knockout (KO) mice die at ~2 months of age mainly due to thymic 
lymphomas 14. Genotyping was performed by PCR using primers suggested by the Jackson 
Laboratory. 
Myocardial infarction 
Myocardial infarction (MI) was performed as previously described 13. Briefly, mice were 
anesthetized using a mixture of isoflurane (2%) and oxygen (0.5 l/min), and maintained under 
anesthesia using isoflurane (1%) and oxygen (0.5 l/min). The mice were ventilated using a rodent 
ventilator. Body temperature was maintained at ~37⁰C using a heating pad. Heart was exposed 
by a left thoracotomy followed by the ligation of left anterior descending artery (LAD) using 7-0 
polypropylene suture. Mice in the sham group underwent the same procedure without the 
ligation of LAD. At the end of the study period, 1 or 3 days post-MI, isolated hearts were used 
for either histology or for molecular analyses.  
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Echocardiography 
Transthoracic two-dimensional m-mode echocardiography was performed using a Toshiba Aplio 
80 Imaging System (Tochigi, Japan) equipped with a 12 MHz linear transducer as previously 
described 15. An individual blinded to the experimental groups recorded the cardiac structural 
parameters.  A second individual read the recordings and calculated the functional parameters of 
the heart.   
Morphometric analyses 
Following MI, hearts were removed and arrested in diastole using KCl (30 mmol/L). After fixing 
with 10% buffered formalin, hearts were cut into 3 transverse sections (base, mid-LV and apex) 
and embedded in paraffin. Cross-sections (4µm think) were stained using Masson’s Trichrome 
stain in order to determine infarct size 3 days post-MI. Infarct size was calculated as the 
percentage of LV circumference occupied by infarct scar 13. Infarct size 1 day post-MI was 
calculated using TTC stained hearts as previously described 16. Masson’s Trichrome stained 
sections were also used to quantify percent fibrosis. 
Myocyte cross-sectional area 
To measure myocyte cross-sectional area, cross-sections (4µm thick) of the heart were stained 
with FITC-labeled wheat germ agglutinin (WGA). The sections were visualized using 
fluorescent microscopy (20X; Nikon) and images were recorded using Retiga 1300 color-cooled 
camera. Suitable area of the section was defined as the one with nearly circular capillary profiles 
and nuclei. Myocyte cross-sectional areas were measured using Bioquant Image analysis 
software (Nashville, TN) as described 15. 
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Terminal deoxynucleotidyl transferase nick end labeling (TUNEL staining) assay  
TUNEL staining was carried out according to manufacturer’s instruction (Cell death detection 
assay; Roche) 13. Sections were counterstained with Hoechst 33258 (Sigma) to identify nuclei. 
The index of apoptosis was calculated as the percentage of apoptotic nuclei/total number of 
nuclei.  
Immunohistochemistry 
Cross-sections of the heart (4µm thick) were deparaffinized and immunostained for neutrophils 
and macrophages using anti-neutrophil (1:100, Santa Cruz) and anti-F4/80 (macrophage; 1:200; 
Santa Cruz) antibodies, respectively. Detection was performed using ABC staining system 
(Santa Cruz). Sections were counterstained with 1% eosin. Expression of α-SMA serves as a 
marker for the differentiation of fibroblasts into myofibroblasts 17. To examine expression of α-
SMA, heart sections were immunostained using anti-α-SMA antibodies (Sigma) as described 13. 
Images were acquired using Nikon TE-2000 microscope equipped with a Regita-1300 color-
cooled camera. Quantitative analysis was carried using Bioquant Image analysis software 
(Nashville, TN). At least five different images within the infarct area from each heart were used 
for quantitative purposes. Images acquired from the septal wall represented non-infarct LV 
region. Images from the sham group were acquired from various regions around the LV.  
Western blot analyses 
LV lysates were prepared in RIPA buffer, separated by SDS-PAGE and transferred to PVDF 
membranes.  The membranes were blocked using either 5% non-fat dry milk or 5% BSA in 
TBST. The membranes were then incubated overnight with antibodies against ATM, TGF-β, 
Bax (Santa Cruz), MMP-9 (Millipore), Bcl-2, p-Akt (ser-473) or p-GSK-3β (ser-9) (Cell 
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Signaling). GAPDH (Santa Cruz) immunostaining or Ponceau-S staining was used as protein 
loading control. Band intensities were quantified using Kodak photo documentation system 
(Eastman Kodak Co.).   
MMP activity 
Gelatin in-gel zymography was used to determine activity of MMP-9 as previously described 18. 
Clear digested bands were quantified using Kodak photo documentation system (Eastman Kodak 
Co.).    
Statistical analyses 
Data are presented as mean ± SEM: Shapiro-Wilk test was used to assess the normality of the 
data. One-way analysis of variance (ANOVA) or Kruskal-Wallis was used for multiple 
comparisons. Pairwise comparisons were carried out using either student’s t-test or Mann-
Whitney U test (two-sample). When comparing BW before and after surgery, a two-tailed paired 
t-test was used. Survival between the two genotypes was analyzed using Kaplan-Meier survival 
analysis. Probability (p) values of <0.05 were considered to be significant.  
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Results 
ATM expression in the heart post-MI  
To investigate expression of ATM in the heart post-MI, left ventricular (LV) lysates were 
prepared from the infarct and non-infarct LV regions of WT and hKO 1 and 3 days post-MI. LV 
lysate prepared from ATM KO heart served as a negative control. Western blot analysis using 
anti-ATM antibodies showed complete absence of ATM protein (~370 kDa) in the LV lysate 
prepared from the KO heart (Fig 2.1A; lane 1). A faint signal for ATM was observed in WT-
sham sample (data not shown). However, clear signal for ATM protein was observed in the non-
infarct and infarct LV regions of WT and hKO hearts 1 and 3 days post-MI (Fig 2.1A & B). 
ATM protein levels were higher in the infarct LV regions when compared to the non-infarct LV 
regions. Overall, ATM protein levels were lower (~50%) in non-infarct and infarct LV regions of 
hKO when compared to the WT counterparts.  
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Figure 2.1. MI increases ATM expression in the heart.  LV lysates prepared from WT-sham, 
ATM KO, and non-infarct (Non) and infarct (Inf) LV regions of WT and hKO 1 and 3 days post-
MI were analyzed by western blot using anti-ATM antibodies. A. 1 day post-MI; B. 3 days post-
MI. Protein loading is indicated by Ponceau-S staining. 
 
Morphological analyses 
No significant difference in morphometric parameters was observed between 1 and 3 day sham 
groups; therefore, 1 and 3 day sham groups were pooled.  Surgery (sham or MI) significantly 
decreased body weights (BW) when compared to the pre-surgery BW with no significant 
differences between the two genotypes. MI increased heart weights (HW) 3 days post-MI in both 
genotypes with no significant difference between the two genotypes. HW/BW ratios were 
significantly higher 1 and 3 days post-MI when compared to their respective sham with no 
significant differences between the two genotypes (Table 2.1).  Infarct sizes between the two 
genotypes were not different at either 1 day or 3 days post-MI (Table 2.2). The survival rate for 
both genotypes 1 day post-MI was 100%, while it was 98.4% for WT and 86.2% for hKO 3 days 
post-MI with no significant difference between the two groups. 
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Table 2.1. Morphometric Measurements 1 and 3 Days Post-MI 
  Pre-BW BW HW HW/BW 
Sham WT (n=11) 26.87 ± 0.82 23.96 ± 1.11@ 124.46 ± 4.02 4.73 ± 0.11 
hKO (n=11) 26.49 ± 0.68 22.78 ± 0.77@ 121.03 ± 4.78 4.96 ± 0.21 
1 Day post-MI 
 
WT-MI (n=17) 28.38 ± 1.04 24.21 ± 1.06@ 135.53 ± 6.98 5.17 ± 0.23# 
hKO-MI (n=11) 26.5 ± 1.07 24.69 ± 2.43 @ 134.01 ± 5.12 5.61 ± 0.14# 
3 Days post-MI  
 
WT-MI (n=15) 24.93 ± 0.89 22.28 ± 0.80@ 143.90 ± 4.91# 6.43 ± 0.24# 
hKO-MI (n=20) 25.39 ± 0.68 23.07 ± 0.61@ 140.17 ± 7.51# 6.07 ± 0.27# 
Values are mean ± SEM.  @p<0.001 vs pre-BW; #p<0.05 vs Sham; BW, body weight; HW, heart 
weight 
 
 
Table 2.2. Infarct size and Myocyte Cross-sectional Area 
  Percent infarct Cross sectional area (mm2) 
Sham WT (n=8) NA 185.06 ± 5.08 
 
hKO (n=7-8) NA 203.72 ± 6.64* 
1 Day Post-MI WT-MI (n=4-7) 32.64 ± 4.07 213.23 ± 9.0# 
 
hKO-MI (n=4-6) 35.13 ± 6.08 203.92 ± 6.19 
3 Days Post-MI WT-MI (n=5-6) 50.41± 2.41 211.36 ± 7.29# 
 
hKO-MI (n=5-7) 51.09 ± 5.78 204.50 ± 8.19 
Values are mean ± SEM.  #p<0.05 vs Sham, *p<0.05 vs WT-Sham 
Echocardiographic studies  
Figure 2.2A exhibits M-mode echocardiography images obtained from sham and MI (1 day post-
MI) groups. No significant difference in echocardiographic parameters was observed between 1 
and 3 day sham groups. Therefore, 1 and 3 day sham groups were pooled. A significant decrease 
(p<0.05) in heart function, as evidenced by a decrease in percent fractional shortening (%FS) and 
ejection fraction (EF), was observed at 1 and 3 day post-MI in both genotypes when compared to 
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their respective sham groups. However, the decrease in %FS and EF was significantly lower in 
hKO-MI versus WT-MI 1 day post-MI. No significant differences in %FS and EF were observed 
between the two genotypes 3 days post-MI (Fig 2.2B and 2.2C). Increased LV end-systolic 
volume (LVESV) is considered as a predictor of mortality post-MI 19.  WT-MI group exhibited a 
significant increase in LVESV and LV end-diastolic volume (LVEDV) 1 and 3 days post-MI 
when compared to WT-sham. In hKO-MI, a significant increase in LVESV and LVEDV was 
observed 1 day, not 3 days, post-MI when compared to hKO-sham. Interestingly, LVESV and 
LVEDV were significantly higher in WT-MI versus hKO-MI at both time points (Fig 2.2D and 
2.2E).  
 
Figure 2.2. ATM deficiency improves LV function. MI was performed in WT and hKO mice. 
Panel A shows M-mode echocardiographic images obtained from sham and 1 day post-MI 
groups. Indices of cardiac function (percent fractional shortening, %FS; ejection fraction, EF) 
and volume (LV end systolic volume, LVESV; LV end diastolic volume, LVEDV) were 
calculated using echocardiographic images 1 and 3 days post-MI. #p<0.005 vs Sham, *p<0.05 vs 
WT-MI; n= 10-12. 
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Inflammatory cell infiltration 
Sham groups exhibited the presence of only a few neutrophils in the heart with no significant 
difference between the two genotypes. MI increased the number of neutrophils in the infarct LV 
regions of both genotypes at both time points when compared to their respective sham groups 
(Fig 2.3A and B). A significant increase in neutrophil number was also observed in the non-
infarct LV region of WT group 1 day post-MI versus WT-sham (Fig 2.3A). Interestingly, the 
number of neutrophils was significantly lower in the infarct and non-infarct LV regions of hKO-
MI when compared to WT-MI 1 day post-MI (Fig 2.3A).  The number of neutrophils in the 
infarct LV region decreased significantly in both MI groups 3 days post-MI. However, the 
number stayed higher in the infarct LV regions when compared to the sham groups and non-
infarct LV regions in both genotypes. There was no significant difference in the number of 
neutrophils between the two genotypes 3 days post-MI, although the number of neutrophils in 
the non-infarct LV region of hKO-MI was significantly higher when compared to hKO-sham 
(Fig 2.3B).  
Sham groups exhibited the presence of a few macrophages in the heart with no significant 
difference between the two genotypes. MI increased the number of macrophages in the infarct 
and non-infarct LV regions of both genotypes when compared to their respective sham groups. 
However, the number of macrophages was significantly lower (p<0.05) in the infarct LV region 
of hKO-MI versus WT-MI 1 day post-MI (Fig 2.3C).  Three days post-MI, the number of 
macrophages was still higher in the infarct LV regions of both genotypes when compared to their 
respective sham groups, however, there was no significant difference between the two 
genotypes. In addition, the number of macrophages in the non-infarct LV region of hKO-MI was 
significantly higher when compared to hKO-sham (Fig 2.3D).  
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Figure 2.3. ATM deficiency results in decreased inflammatory cells in the infarct LV region 1 
day post-MI. Cross-sections of the heart post-MI were immunostained using anti-neutrophil 
(A&B) and anti-F4/80 (macrophage; C&D) antibodies. The number of immune-positive cells 
was quantified using Bioquant Image analysis software. Quantitative analyses of neutrophils 1 
(A) and 3 (B) days post-MI. Quantitative analyses of macrophages 1 (C) and 3 (D) days post-MI.  
#p<0.05 vs Sham, $p<0.05 vs Non, *p<0.05 vs WT; n=4-6.  
 
Fibrosis, apoptosis, and myocyte cross-sectional area  
Quantitative analysis of fibrosis using Masson’s Trichrome-stained sections revealed no change 
in fibrosis between 1 and 3 day sham groups, therefore the sham groups were pooled.  The 
amount of fibrosis was significantly higher in hKO-sham versus WT-sham. MI increased fibrosis 
in the infarct LV region of both groups 3 days post-MI. However, the amount of fibrosis was 
significantly higher in hKO-MI versus WT-MI (Fig 2.4). 
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Figure 2.4. ATM deficiency results in increased fibrosis. Masson’s trichrome stained sections of 
the heart were used for quantitative measurement of fibrosis. Upper panel depicts Masson’s 
trichrome-stained sections exhibiting fibrosis in WT and hKO hearts 3 days post-MI. Lower 
panel exhibits quantitative analysis of fibrosis. #p<0.05 vs Sham, *p<0.05 vs WT-MI;  n=5-6. 
 
Only a few apoptotic cells were detected in the sham and non-infarct LV regions of WT-
MI and hKO-MI 1 day post-MI. MI significantly increased the number of apoptotic cells in the 
infarct LV region of both genotypes 1 day post-MI (Fig 2.5A). However, the number of 
apoptotic cells was significantly greater in the hKO-MI (p<0.05) versus WT-MI. Three days 
post-MI, the level of apoptosis in the infarct LV regions decreased in both genotypes versus 1 
day post-MI. However, it remained higher when compared to their respective sham groups and 
non-infarct LV regions (Fig 2.5B). Interestingly, hKO-MI continued to have significantly higher 
number of apoptotic cells (p<0.05) in the infarct LV region versus WT-MI. hKO-MI also 
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exhibited a significant increase (p<0.05) in apoptosis in the non-infarct LV region when 
compared to hKO-sham and non-infarct WT-MI.  
 
 
Figure 2.5. ATM deficiency results in enhanced apoptosis post-MI. Quantitative analysis of 
cardiac cell apoptosis in the non-infarct (Non) and infarct (Inf) LV regions 1 (A) and 3 (B) days 
post-MI. Upper panels depict TUNEL-stained and Hoechst-stained images obtained from WT 
and hKO hearts 1 and 3 days post-MI.  Red fluorescent staining indicates TUNEL-positive 
(apoptotic) nuclei, while blue fluorescent staining indicates total number of nuclei. The lower 
panels exhibit quantitative analysis. #p<0.05 vs Sham *p<0.05 vs WT, $p<0.05 vs Non; n=4-6. 
 
Myocyte cross-sectional area was significantly higher in hKO-sham group versus WT-
sham. Myocyte cross-sectional area in the non-infarct LV region remained unchanged in the 
hKO-MI group 1 and 3 days post-MI. However, a significant increase in myocyte cross-sectional 
area was observed in WT-MI group when compared to WT-sham 1 and 3 days post-MI (Table 
2.2). 
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Expression of TGF-β1 
The anti-inflammatory cytokine TGF-β1 plays an important role in myocardial remodeling post-
MI via its involvement in the differentiation of fibroblasts into myofibroblasts and ECM 
deposition 8. One source of TGF-β1 is macrophages as they phagocytose apoptotic neutrophils 12. 
Western blot analysis showed no presence of active TGF-β1 protein (23 kDa band) in the sham 
groups, non-infarct or infarct LV regions 1 day post-MI (data not shown). Presence of active 
TGF-β1 band was only observed in the infarct LV regions of both genotypes 3 days post-MI. 
However, the levels of active TGF-β1 were significantly higher in the WT-MI versus hKO-MI 
(Fig 2.6). 
 
Figure 2.6. Expression of TGF-β1.  Total LV lysates, prepared from sham and non-infarct (Non) 
and infarct (Inf) LV regions 3 days post-MI, were analyzed by western blot using anti-TGF-β1 
antibodies. The upper panel depicts autoradiogram indicating immunostaining for active TGF- 
β1 (~26 kDa band) and GAPDH. The lower panel exhibits quantitative analysis of TGF- β1 in 
the Inf LV regions of WT and hKO groups normalized to GAPDH. *p<0.05 vs WT-Inf; n=8-9. 
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Expression of α-smooth muscle actin (α-SMA) 
Increased α-SMA expression is considered as a marker for the differentiation of fibroblasts into 
myofibroblast 20. One day post-MI, little to no expression of α-SMA expression was observed in 
the infarct LV regions of either group (data not shown). Three days post-MI, a significant 
increase in α-SMA expression was observed in the infarct LV region of both genotypes when 
compared to their respective sham groups. However, the increase in α-SMA expression was 
significantly higher (p<0.05) in hKO-MI versus WT-MI (Fig 2.7).    
 
Figure 2.7. Quantitative analysis of α-smooth muscle actin (α-SMA) expression. Cross-sections 
of the heart were immunostained using anti-α-SMA antibodies. Upper panel depicts α-SMA-
stained images from the infarct (Inf) LV regions of WT and hKO hearts 3 days post-MI. Lower 
panel exhibits quantitative immunocytochemical analysis of α-SMA in sham and Inf LV regions 
3 days post-MI. #p<0.05 vs Sham, *p<0.05 vs WT-Inf; n=4-5. 
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Expression and activity of MMP-9 
MMP-9 regulates the remodeling processes of the heart that involves inflammation and fibrosis 
21
. MMP-9 levels in the ischemic region of the heart increase within minutes after MI and stay 
higher during the first few days in animal models 21;22. Western blot analysis revealed increased 
MMP-9 protein levels in the infarct LV regions of both genotypes 1 day post-MI when compared 
to their respective sham groups. However, no significant differences were observed between the 
two genotypes (Fig 2.8A). MMP-9 expression remained higher in the infarct LV regions of both 
genotypes 3 days post-MI with no significant difference between the two genotypes (Fig 2.8B). 
In-gel zymography revealed increased MMP-9 activity in the infarct LV regions of both 
genotypes (data not shown).  
 
Figure 2.8. Expression of MMP-9. Total LV lysates, prepared from sham, non-infarct (Non) and 
infarct (Inf) LV regions 1 and 3 day post-MI, were analyzed by western blot using anti-MMP-9 
antibodies. The upper panels depict autoradiograms indicating immunostaining for MMP-9 and 
GAPDH. The lower panels exhibit quantitative analyses of MMP-9 normalized to GAPDH. A. 
MMP-9 protein levels 1 day post-MI (n=6). B. MMP-9 protein levels 3 days post-MI (n=5) 
#p<0.05 vs sham. 
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Activation and expression of apoptosis-related proteins  
Increased phosphorylation (activation) of Akt is generally considered as an anti-apoptotic signal 
23
. Phosphorylation of Akt remained unchanged in the WT-MI 1 day post-MI. However, Akt 
phosphorylation was significantly lower in the non-infarct and infarct LV regions of hKO-MI 
versus hKO-sham. In addition, Akt phosphorylation was significantly lower in the hKO-MI 
infarct LV region versus WT-MI infarct LV region (Fig 2.9A). No significant change in Akt 
phosphorylation was observed among the groups 3 days post-MI (data not shown).  
 
 
Figure 2.9. Phosphorylation of Akt and GSK-3β. Total LV lysates, prepared from sham, non-
infarct (Non) and infarct (Inf) LV regions 1 day post-MI, were analyzed by western blot using 
phospho-specific antibodies for Akt (ser-473) and GSK-3β (ser-9). The upper panels depict 
autoradiograms indicating immunostaining for p-Akt, p-GSK-3β and GAPDH. The lower panels 
exhibit quantitative analyses of p-Akt (A) and p-GSK-3β (B) normalized to GAPDH. #p<0.05 vs 
Sham; *p<0.05 vs WT-Inf; n=6. 
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Activation of GSK-3β plays a pro-apoptotic role in β-adrenergic receptor-stimulated 
apoptosis 24. Phosphorylation of N-terminal serine-9 inactivates GSK-3β 25. GSK-3β 
phosphorylation (serine-9) was lower in the non-infarct LV region of WT-MI versus WT-sham 1 
day post-MI.  In the infarct LV region, hKO-MI exhibited a significant decrease in GSK-3β 
phosphorylation when compared to hKO-sham and WT-MI infarct LV region (Fig 2.9B). Three 
days post-MI, GSK-3β phosphorylation was significantly lower (p<0.05) in infarct and non-
infarct region of both WT and hKO mice when compared to their respective sham groups with 
no significant difference between the two MI groups (data not shown). 
Bax, a pro-apoptotic protein, is a transmembrane protein located in the outer 
mitochondrial membrane. Homodimerization of Bax increases cytochrome c release resulting in 
the induction of apoptosis. Bcl-2 can inhibit Bax induced apoptosis by forming a heterodimer 
with Bax 26. Western blot analyses showed no difference in Bax or Bcl-2 protein levels between 
the two genotypes in the infarct LV regions 1 day post-MI (data not shown). Bax expression was 
significantly higher in the infarct LV region of hKO when compared to WT group 3 days post-
MI. However, there was no significant difference in Bcl2 expression between the two genotypes 
3 days post-MI (Fig 2.10).  
51 
 
 
Figure 2.10. Expression of Bax and Bcl-2. Total LV lysates, prepared from infarct LV regions 3 
days post-MI, were analyzed by western blot using anti-Bax and anti-Bcl-2 antibodies. The 
upper panels depict autoradiograms indicating immunostaining for Bax (A), Bcl-2 (B) and 
GAPDH. The lower panels exhibit quantitative analyses of Bax (A) and Bcl-2 (B) normalized to 
GAPDH. *p<0.05 vs WT-MI; n=6-8. 
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Discussion 
Previously we provided evidence that ATM deficiency results in improved heart function 
and decreased LV dilatation 7 days post-MI. A major finding of this study is that ATM 
deficiency associates with delayed inflammatory response post-MI.  This is evidenced by the 
decreased number of neutrophils and macrophages 1 day post-MI, and decreased expression of 
TGF-β1 in the infarct area 3 days post-MI.  ATM deficiency also associated with increased 
apoptosis, fibrosis and expression of α-SMA in the heart post-MI. Activation of pro-survival 
kinase, Akt, was lower, while activation of pro-apoptotic kinase, GSK-3β, was higher in ATM 
deficient hearts 1 day post-MI. The data presented here support our previous findings 13, and 
suggest multifaceted role of ATM in myocardial remodeling post-MI.  
ATM normally becomes activated in response to DNA damage, particularly due to the 
formation of DNA double-strand breaks. This activation occurs due to its autophosphorylation 
on Ser1981 27. Genotoxic agents, oxidative stress and growth factors also increase ATM 
expression in certain cell types 5;6. In peripheral blood mononuclear cells, maximum increase in 
ATM expression in response to  mitogenic stimuli was observed 3-4 days after exposure 6. 
Previously, we have shown that β-AR stimulation increases ATM expression in adult rat 
ventricular myocytes and heart 28. This study provides evidence that MI increases ATM 
expression in the heart. The increase in ATM could be a result of either increased sympathetic 
nerve activity and/or increased oxidative stress, both of which increase in the heart following MI 
29;30
.  
MI usually leads to increased chamber diameter which results in increased loading 
capacity of the heart represented by increased LVESV and LVEDV. Increased LVESV is 
suggested as one of the major determinants of survival post-MI 19. Previously, we provided 
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evidence that deficiency of ATM attenuates LV dysfunction and dilatation 7 days post-MI 13. 
The data presented here suggest that the attenuation of LV dysfunction and dilation during ATM 
deficiency can be observed as early as 1 day post-MI. ATM deficient mice exhibit a lesser 
degree of impairment in systolic parameters as evidenced by higher %FS and EF 1 day post-MI. 
It was interesting to note that %FS and EF were not different between the two genotypes 3 days 
post-MI, although LVESV and LVEDV were significantly lower in ATM deficient hearts at both 
time points. The better LV function 1 day post-MI during ATM deficiency did not correlate with 
infarct size since infarct sizes remained unchanged between the two genotypes 1 and 3 days post-
MI. Other factors such as infarct thickness, myocardial fibrosis, and myocyte hypertrophy also 
influence heart function post-MI 31. ATM deficient hearts exhibited increased infarct thickness, 
increased fibrosis and increased α-SMA expression 7 days post-MI 13. While increased levels of 
fibrosis late post-MI is a predictor of heart failure, early fibrosis may play a protective role in the 
healing process by preventing infarct expansion  32. Infarct thickness remained unchanged 
between the two genotypes 1 and 3 days post-MI. Expression of α-SMA was higher in ATM 
deficient hearts 3 days post-MI. Therefore, slightly better function exhibited by ATM deficient 
hearts 1 day post-MI cannot be explained by infarct thickness or expression of α-SMA. ATM 
deficiency associates with increased myocyte cross-sectional area and fibrosis at basal levels, 
and results in delayed inflammatory response post-MI. Therefore, myocyte hypertrophy, 
myocardial fibrosis and delayed inflammatory response may help explain better function during 
ATM deficiency 1 day post-MI. 
Neutrophils begin to infiltrate into the infarcted myocardium within hours of the ischemic 
event peaking 24 hours post-MI 9. Neutrophil infiltration activates resident monocytes to 
differentiate into macrophage in the infarct LV region shortly after MI. Macrophage number 
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stays relatively stable from 1 - 7 days post-MI 12. Macrophages play a number of roles in post-MI 
healing process. They phagocytose dead cells, tissue debris and apoptotic neutrophils. In 
addition, they secret MMPs and their inhibitors to aid in extracellular matrix reorganization 12.  
Consistent with these data, we observed increased number of neutrophils and macrophages in the 
myocardium of both genotypes at both time points. Interestingly, the number of inflammatory 
cells was significantly lower in ATM deficient hearts 1 day post-MI. Three days post-MI, the 
number of neutrophils decreased, while the number of macrophages increased in the infarct LV 
regions of both genotypes. However, the number of neutrophils and macrophages was not 
significantly different between the two genotypes. These data suggest a delayed inflammatory 
response during ATM deficiency early post-MI. Neutrophils are recruited to the site of 
inflammation via chemokines and cytokines 8. However, signals such as lactoferrin and annexin 
1 released by apoptotic cells can inhibit recruitment of neutrophils to the site of the injury 33;34. 
ATM deficient hearts exhibit increased apoptotic response when compared with their WT 
counterparts. This increase in apoptosis during ATM deficiency can have an inhibitory effect on 
neutrophil migration.  A decrease in inflammatory receptors (selectins, integrins and adhesion 
receptors) may also influence neutrophil recruitment 35. Further investigations are required to 
investigate the involvement of these molecular signals in the inflammatory response in the heart 
post-MI during ATM deficiency. 
Phagocytosis of neutrophils by macrophages initiates the release of anti-inflammatory 
signal involved in resolution of inflammation 12. Suppression of inflammatory response may 
involve a variety of signals, including a secreted protein TGF-β. TGF-β1, an anti-inflammatory 
signal, can affect infarct healing by modulating the release of cytokines and chemokines, 
synthesis of ECM proteins and transdifferentiation of fibroblasts into myofibroblasts 36. In rat MI 
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model, increased expression of TGF-β1 mRNA was observed 3 days post-MI 37. Here we 
observed increased levels of active TGF-β1 in the heart 3 days post-MI. ATM deficiency 
associated with decreased macrophage count 1 day post-MI and decreased active TGF-β1 levels 
3 days post-MI. This is consistent with the fact that macrophages are a major producer of TGF-β 
post-MI 8. It is interesting to note that ATM deficiency also associates with increased expression 
of α-SMA and fibrosis 3 days post-MI. While TGF-β is a known activator of fibroblast 
differentiation, TGF-β alone does not trigger fibroblast differentiation. Myofibroblast 
transformation also requires specialized ECM proteins like the ED-A splice variant of fibronectin 
as well as increased mechanical stress. Under normal conditions, fibroblasts are protected against 
mechanical stress via cross-linkage of the ECM. During injury, the ECM begins remodeling 
itself leading to the activation of myofibroblast 38. Therefore, it is possible that the enhanced 
apoptosis in the heart during ATM deficiency increases mechanical stress leading to enhanced 
myofibroblast activation.  
Extracellular matrix (ECM) plays a critical role in the restructuring of the heart post-MI. 
Changes in MMP abundance and activity is shown to be associated with changes in ECM 
deposition and myocardial remodeling post-MI 21. MMP-9 levels increase in the heart within 
minutes and remain elevated during the first few days post-MI 22;39. Previously, we have shown 
that ATM deficiency associates with higher MMP-9 protein levels and activity in the infarct LV 
region 7 days post-MI when compared to WT 13. Neutrophils are identified as a source of MMP-
9 during acute ischemia/reperfusion myocardial injury 40. This expression of MMP-9 was 
suggested to aid in the migration of neutrophils. Here, we observed increased MMP-9 protein 
levels in both genotypes at both time points. However, MMP-9 protein levels were not different 
between the two MI groups. Furthermore, reduced neutrophil numbers did not result in reduced 
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MMP-9 expression during ATM deficiency, suggesting other cell types of the heart post-MI may 
participate in MMP-9 expression 21. Of note, neutrophils isolated  from MMP-9 null mice show 
no defect in transendothelial migration under flow in vitro 41.  
The extent of cardiac myocyte death is a major determinant of myocardial remodeling 
post-MI. Myocyte death can occur due to necrosis and apoptosis in the ischemic zone. During 
the inflammatory phase, infiltrated neutrophils also die due to apoptosis as part of the healing 
process 36. Cardiac cell apoptosis was significantly higher in ATM deficient hearts 1 and 3 days 
post-MI. Although not investigated, this number most likely includes apoptotic neutrophils and 
macrophages. Mitochondria play a crucial role in determination of cell fate with respect to cell 
survival and apoptosis 42. Bcl2 family proteins, Bcl2 and Bax, modulate mitochondrial 
membrane potential and activation of caspases 26. ATM deficiency resulted in enhanced 
expression of Bax in the infarct LV region. Although there was no change in Bcl2 expression, 
the increase in Bax may induce loss of mitochondrial membrane potential and apoptosis. The 
increase in apoptotic cells during ATM deficiency also associated with decreased activation of 
anti-apoptotic kinase, Akt and enhanced activation of pro-apoptotic kinase, GSK-3β 1 day post-
MI. In fact, Akt exerts its anti-apoptotic effect, in part, through inactivation of GSK-3β 43. 
Previously, we have shown decreased activation of Akt in the myocardium of mice lacking ATM 
in response to β-AR stimulation 15. However, β-AR stimulation had no effect on GSK-3β 
activation during ATM deficiency. Collectively, these data suggest activation of Akt, via ATM, 
as a common signaling event during myocardial stress. Activation of GSK-3β appears to be 
modulated differentially in response to different myocardial stress during ATM deficiency.  
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In summary, ATM deficiency results in improved heart function as determined by a 
decrease in dilative remodeling and inflammatory response acute post-MI. However, it also 
associates with negative remodeling as determined by increased apoptosis and decreased 
activation of anti-apoptotic kinase, Akt. In addition, ATM deficiency results in an increase in 
fibrosis and expression of α-SMA. These studies, together with our previous findings 13, suggest 
that ATM has the potential to modulate the remodeling processes of the heart post-MI. Further 
investigations are needed to define the long-term impact of ATM deficiency in the healing 
processes of the heart post-MI. 
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CHAPTER 3 
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Abstract 
Ataxia telangiectasia mutated kinase (ATM) is a cell cycle checkpoint protein activated in 
response to DNA damage. We recently reported that ATM plays a protective role in myocardial 
remodeling following β-adrenergic receptor stimulation. Here we investigated the role of ATM 
in cardiac remodeling using myocardial infarction (MI) as a model. Methods and Results: Left 
ventricular (LV) structure, function, apoptosis, fibrosis, and protein levels of apoptosis- and 
fibrosis-related proteins were examined in wild-type (WT) and ATM heterozygous knockout 
(hKO) mice 7 days post-MI. Infarct sizes were similar in both MI groups. However, infarct 
thickness was higher in hKO-MI group. Two dimensional M-mode echocardiography revealed 
decreased percent fractional shortening (%FS) and ejection fraction (EF) in both MI groups 
when compared to their respective sham groups. However, the decrease in %FS and EF was 
significantly greater in WT-MI vs hKO-MI. LV end systolic and diastolic diameters were greater 
in WT-MI vs hKO-MI. Fibrosis, apoptosis, and α-smooth muscle actin staining was significantly 
higher in hKO-MI vs WT-MI. MMP-2 protein levels and activity were increased to a similar 
extent in the infarct regions of both groups. MMP-9 protein levels were increased in the non-
infarct region of WT-MI vs WT-sham. MMP-9 protein levels and activity were significantly 
lower in the infarct region of WT vs hKO. TIMP-2 protein levels similarly increased in both MI 
groups, whereas TIMP-4 protein levels were significantly lower in the infarct region of hKO 
group. Phosphorylation of p53 protein was higher, while protein levels of manganese superoxide 
dismutase were significantly lower in the infarct region of hKO vs WT. In vitro, inhibition of 
ATM using KU-55933 increased oxidative stress and apoptosis in cardiac myocytes. 
Conclusion: Deficiency of ATM improves heart function 7 days post-MI. However, it has 
adverse effect on myocardial remodeling with increased apoptosis and fibrosis. 
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Introduction 
Myocardial infarction (MI) induces a series of molecular and structural changes in the 
left ventricle leading to a progressive decline in LV performance [1–3].  The limited capacity for 
regeneration of myocytes in the adult heart suggests that cardiac myocyte loss due to apoptosis 
may contribute to the progression of heart failure. Dynamic synthesis and breakdown of 
extracellular matrix also plays a significant role in myocardial remodeling post-MI [4,5]. 
Therefore elucidation of events involved in the repair of the heart is an important clinical 
determinant of survival post-MI [6].  
Ataxia telangiectasia mutated kinase (ATM) is a multifunctional kinase that affects 
multiple downstream targets in response to cellular stress or damage.  Mutation or deficiency of 
ATM causes a hereditary multi-systemic disease called Ataxia telangiectasia (A-T). Individuals 
with mutations in both copies of the ATM gene suffer from increased susceptibility to ionizing 
radiation, predisposition to cancer, insulin resistance, immune deficiency, and premature aging. 
Carriers of one mutated allele at the A-T locus make up ~1.4 to 2% of the general population. 
These individuals with an ATM mutation in one allele are spared from most of the symptoms of 
A-T, but are more susceptible to cancer and ischemic heart disease [7–9].  
Previously, a search to identify novel apoptosis-related genes using Super-Array 
technique followed by RT-PCR analyses revealed that β-adrenergic receptor (β-AR) stimulation 
increases expression of ATM in the heart and in adult cardiac myocytes [10]. Using ATM 
heterozygous knockout (hKO) mice and chronic β-AR stimulation as a model of myocardial 
remodeling, we provided evidence that ATM plays an important role in β-AR-stimulated 
myocardial remodeling with effects on ventricular function, apoptosis and fibrosis [10]. Recently, 
using ATM-/- mice, we have shown that lack of ATM induces structural and functional changes 
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in the heart with enhanced myocardial fibrosis and myocyte hypertrophy. β-AR-stimulated 
apoptosis in WT hearts associated with p53- and JNKs-dependent mechanism, while decreased 
Akt activity may play a role in increased myocyte apoptosis in the absence of ATM [11]. The 
objective of this study was to investigate the role of ATM in myocardial remodeling 7 days post-
MI. The data presented here show that deficiency of ATM affects heart function, infarct 
thickness, fibrosis, apoptosis and expression of fibrosis- and apoptosis-related proteins.  
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Methods 
Vertebrate animals 
Age-matched (~ 4 months old) male and female ATM deficient mice were used as previously 
described [10]. Heterozygous knockout (hKO) and wild type (WT) ATM mice, purchased from 
the Jackson Laboratory, were of 129xblack Swiss hybrid background.  Genotyping was 
performed by polymerase chain reaction (PCR) using primers suggested by the Jackson 
Laboratory. The absence of both ATM alleles produces a lethal phenotype at ~2 months of age 
mainly due to thymic lymphomas [12,13].  
Ethics statement 
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All of the 
experiments were performed in accordance with the protocols approved by the East Tennessee 
State University Animal Care and Use Committee.  
Myocardial infarction 
MI and measurements were performed as previously described [14–16]. The left anterior 
descending coronary artery was occluded using a 7-0 mm silk suture. Sham animals underwent 
the same surgery without ligation of the coronary artery.  
Echocardiography  
Transthoracic two-dimensional M-mode echocardiography was performed as previously 
described [10,11]. All echocardiographic assessments and measurements were performed by the 
same investigator.  A second person also performed measurements on a separate occasion using 
the same recordings with no significant differences in interobserver variability.  
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Morphometric analyses 
Following MI, hearts were removed and arrested in diastole using KCl (30 mmol/L) followed by 
perfusion fixation with 10% buffered formalin. Infarct size was measured using Masson’s 
trichrome stained sections as previously described  [14,16]. Infarct size was calculated as the 
percentage of LV circumference occupied by infarct scar. Infarct thickness was calculated using 
mid-myocardial slides, averaging three equally spaced measurements along the infarct wall.  
Cross sections (4µm thick) were stained with Masson’s trichrome for the measurement of 
fibrosis using Bioquant image analysis software (Nashville,TN). 
Apoptosis 
To detect apoptosis, TUNEL-staining was carried out as previously described [10,11]. Hoechst 
33258 (10 µM; Sigma) staining was used to count the total number of nuclei. Apoptosis was 
calculated as the percentage of apoptotic cardiac cell nuclei / total number of nuclei. To identify 
apoptosis associated with cardiac myocytes, the sections were immunostained using α-
sarcomeric actin antibodies (1:50, 5C5 clone; Sigma, St. Louis, MO). TUNEL-positive nuclei 
that were clearly seen within cardiac myocytes were counted. The number of apoptotic myocyte 
nuclei was counted, and index of apoptosis was calculated as the percentage of apoptotic 
myocyte nuclei/total number of nuclei. In isolated cells, the percentage of TUNEL-positive cells 
(relative to total myocytes) was determined by counting ~200 cells in 10 randomly chosen fields 
per coverslip for each experiment. 
Immunohistochemistry 
Sections (4µm thick) were deparrafinized and stained with anti-α-smooth muscle actin (α-SMA) 
as described [11]. The sections were visualized using fluorescent microscopy (Nikon) and images 
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were acquired using Retiga 1300 color-cooled camera. Images were quantitatively analyzed 
using Bioquant Image analysis software (Nashville, TN).  
 
Western blot analysis  
LV lysates were prepared in RIPA buffer as previously described [17]. Protein lysates (50 µg) 
were separated by SDS-PAGE (10%) and transferred to a PVDF membrane (240 mA, 2.5 h). The 
membranes were incubated with antibodies against p-p53 (serine-15; Cell Signaling), MMP-9 
and MMP-2 (Millipore), TIMP-2 and TIMP-4 (Chemicon), and SOD-2 (Santa Cruz).  
Membranes were stripped and probed with GAPDH (Santa Cruz) as a protein loading control. 
Band intensities were quantified using Kodak photodocumentation system (Eastman Kodak Co.). 
The data are presented as fold change vs WT-sham.  
In-gel zymography  
In gel zymography was performed on 50 µg of LV lysates from WT-MI and hKO-MI hearts as 
previously described [18]. Clear and digested regions representing MMP-2 and MMP-9 activity 
were quantified using a Kodak documentation system.  
Cell isolation, culture and treatment 
Adult rat ventricular myocytes (ARVMs) were isolated as previously described [19]. ARVMs 
were plated in Dulbecco’s modified Eagle’s medium (DMEM; Mediatech) supplemented with 
HEPES (25 mM), BSA (0.2%), creatine (5 mM), L-carnitine (2 mM), taurine (5 mM) and 0.1% 
penicillin-streptomycin at a density of 30–50 cells/mm2 on coverslips precoated with laminin 
(1µg/cm2). ARVMs cultured for 24 h were treated with KU-55933 (KU), a specific inhibitor of 
ATM [20], for 24 h. Apoptosis was measured using TUNEL-assay as described above.  
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Detection of oxidative stress 
To detect oxidative stress, ARVMs were treated with KU (0.1 µM and 1 µM) for 3h.  Cells were 
then stained using total reactive oxygen species (ROS)/superoxide detection kit (Enzo Life 
Sciences) and visualized using fluorescent microscopy. The number of ROS-positive cells 
(relative to total myocytes) was determined by counting ~100 cells in 10 randomly chosen fields 
per coverslip for each experiment. 
Statistical analyses  
Data are represented as mean ± SEM.  Data were analyzed using student’s t test or one-way 
analysis of variance (ANOVA) and a post hoc Tukey’s test. Probability (p) values of <0.05 were 
considered to be significant. 
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Results 
 
Morphometric studies and mortality 
Body weights remained unchanged among the sham and MI groups. Heart weight (HW) and HW 
to body weight ratios were increased in both MI groups (p<0.001 vs sham; n=6-12; Table 3.1) 
with no significant difference between the two MI groups. The mortality rates 7 days post-MI 
were 35% and 18% in WT and hKO mice, respectively. Masson’s trichrome staining of the mid-
LV sections is shown in figure 1A. Infarct size measured as a percentage of the LV 
circumference occupied by scar tissue was not different between the WT-MI and hKO-MI 
groups (p=NS, Fig 3.1B). However, infarct thickness measured from mid-myocardial sections 
was significantly greater in hKO-MI group versus WT-MI (Fig 3.1C).  
 
Table 3.1. Morphometric Measurements 7 Days Post-MI 
 WT-Sham (n=6) hKO-Sham (n=7) WT-MI (n=10) hKO-MI (n=12) p 
BW 24.41 ± 0.96 26.49 ± 1.71 23.89 ± 0.76 23.43 ± 0.61  
HW 125.22 ± 7.74 139.08 ± 12.40 153.93 ± 5.27* 158.50 ± 5.93* <0.001 
HW/BW 5.11 ± 0.12 5.25 ± 0.04 6.48 ± 0.33* 6.86 ± 0.43* <0.001 
 
Values are mean ± SEM; *comparison between sham and MI group. 
 
 Figure 3.1. Infarct size and thickness
hearts were analyzed for the measurement of infarct size and thickness. A. Transverse sections of 
the mid-myocardium from WT and hKO
and thickness (C) as measured from trichrome stained hearts; *p<0.05 vs WT; n=5
 
Echocardiographic studies  
No significant differences in the echocardiographic parameters were observed between the two 
sham groups. M-mode echocardiography revealed a significant decrease in percent fractional 
shortening (%FS) and ejection fraction (EF) in both MI groups when compared
respective sham groups. However, the decrease in %FS and EF was significantly greater in the 
WT-MI group when compared to hKO
LV end systolic (LVESD) and diastolic (LVEDD) diameters in both MI gro
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. Masson’s trichrome stained sections from WT and hKO 
 hearts post-MI. Quantitative analysis of infarct size (B) 
-MI (#p<0.05 vs WT-MI; Fig 3.2A & B). MI increased 
ups. However, the 
 
-7. 
 to their 
 increase in LVEDD and LVESD was significantly lower in hKO
MI group (#p<0.05 vs WT-MI; Fig 
 
Figure 3.2. ATM deficiency improves LV function 7 days post
(n=10) and ATM hKO (n=12) mice. Indices of cardiac function (percent fractional shortening, 
%FS; ejection fraction, EF) and structure (LV end diastolic diameter, LVEDD; LV end systolic 
diameter, LVESD) were measured using echocardiography 7 days after MI. A. %FS; B. EF; C, 
LVEDD; D. LVESD; *p<0.05 vs sham; 
 
Fibrosis and Apoptosis 
Quantitative analysis of fibrosis using trichrome stained sections revealed increased fibrosis in 
hKO-sham group vs WT-Sham. MI increased fibrosis in the border and infarc
both groups when compared to their respective non
76 
-MI when compared to the WT
3.2C & D).  
-MI. MI was performed in WT 
#p<0.05 vs WT-MI; n=10-12. 
-infarct LV regions.  Interestingly, the level 
-
 
t LV regions of 
 of fibrosis was greater in the border and infarct regions of hKO
WT-MI (Fig 3.3 A&B).  
 
Figure 3.3. Analysis of fibrosis. Masson’s trichrome stained sections of the heart were used for 
quantitative measurement of fibrosis. A. 
fibrosis in WT and hKO mice 7 days post
infarct LV region; INF, infarct; *p<0.05 vs sham; #p<0.05 comparisons between WT and hKO 
groups; $p<0.05 vs border; n=6-7. 
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-MI group when compared to the 
Masson’s trichrome-stained sections demonstrating 
-MI. B. Quantitative analysis of fibrosis.
 
 
 NINF, non-
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Analysis of apoptosis using TUNEL-staining assay revealed increased apoptosis in the 
hKO-sham vs the WT-sham group. The number of apoptotic cells and myocytes remained 
unchanged in the non-infarct LV regions when compared to the sham groups (Fig 3.4 B&C). MI 
increased the number of apoptotic cells in the border and infarct LV regions of both groups when 
compared to the sham and non-infarct LV regions (Fig 3.4 A&B). In the border area, the number 
of apoptotic cells as well as myocytes was significantly higher in hKO vs WT group. In the 
infarct LV region, the number of apoptotic cells was significantly lower in hKO vs WT group 
(Fig 3.4B), while the number apoptotic myocytes remained unchanged between WT and hKO 
(Fig 3.4C).   
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Figure 3.4. Analysis of apoptosis. A. TUNEL-stained images from the border regions of WT and 
hKO hearts post-MI. B. Quantitative analysis of cardiac cell apoptosis in the non-infarcted 
(NINF), border and infarct (INF) regions of WT and hKO mice 7 days post-MI. C. Quantitative 
analysis of myocyte apoptosis in the NINF, border and INF regions of WT and hKO mice 7 days 
post-MI. *p<0.05 vs sham; #p<0.05 comparisons between WT and hKO groups; $p<0.05 vs 
border; n=4.   
 
Expression of α-smooth muscle actin (α-SMA) 
Expression of α-SMA serves as a marker for the differentiation of fibroblasts into myofibroblasts 
[21–23]. MI increased α-SMA expression in the infarct LV regions of both groups (Fig 3.5A). 
Quantitative immunohistochemical analysis of heart sections revealed increased α-SMA 
expression in the infarct LV region of hKO when compared to the WT group (Fig 3.5B).   
 Figure 3.5. Expression of α-smooth muscle actin (
infarct LV regions of WT and hKO hearts post
of α-SMA expression in the infarct (INF) region of WT and hKO mice 7 days post
vs WT-INF; n=4. 
 
Expression of matrix metalloproteinases (MMPs
 Western blot analyses of LV lysates revealed no significant increase in MMP
the non-infarct LV regions of both MI groups when compared to sham. MMP
were significantly higher in the infarct region of both MI groups when compared to sham. In the 
hKO group, the increase in MMP
when compared to the non-infarct region (Fig 
80 
α-SMA). A. α-SMA-stained images
-MI. B. Quantitative immunohistological analysis 
) and tissue inhibitors of MMPs (TIMPs)
-2 protein levels in 
-2 protein levels was significantly greater in the infarct region 
3.6A). MMP-9 protein levels were increased in the
 
 from the 
-MI. #p<0.05 
 
-2 protein levels 
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non-infarct region and decreased in the infarct region of the WT group when compared to sham. 
No such changes in MMP-9 protein levels were observed in the hKO group. In the infarct region, 
MMP-9 protein levels were significantly greater in the hKO group when compared to the WT 
(Fig 3.6B). Analysis of MMPs activity using in-gel zymography showed no difference in MMP-
2 activity the infarct LV regions between the two MI groups (Fig 3.6C). However, MMP-9 
activity in the hKO was significantly higher in the hKO group when compared to WT (Fig 3.6D). 
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Figure 3.6. Expression and activity of MMPs. A & B. Total LV lysates (50 µg), prepared from 
sham and non-infarct (NINF) and infarct (INF) LV regions, were analyzed by western blot using 
anti-MMP-2 (A) and anti-MMP-9 (B) antibodies. The upper panels show autoradiograms 
indicating immunostaining for MMP-2, MMP-9, and GAPDH. The lower panels exhibit 
quantitative analyses of MMP-2, MMP-9 normalized to GAPDH. *p<0.05 vs sham; #p<0.05 vs 
NINF; $p<0.05 vs WT-INF; n=7. C&D.  Total LV lysates (50 µg), prepared from the infarct LV 
regions were analyzed by in-gel zymography. C. MMP-2 activity. D. MMP-9 activity. *p<0.05 
vs WT-MI; n=3.  
 
TIMP-2 is suggested to inhibit MMP-2 activity [4], while TIMP-4 is predominantly 
expressed in the heart [24] . Western blot analyses showed no immunostaining for TIMP-2 in the 
sham groups. MI increased TIMP-2 protein levels in the non-infarct and infarct regions of the 
heart in both groups. However, TIMP-2 protein levels were significantly greater in the infarct 
region when compared to the non-infarct LV region with no significant difference between the 
 WT and hKO groups (Fig 3.7A). On the contrary, TIMP
both the sham groups. MI decreased TIMP
groups. TIMP-4 protein levels were significantly lower in hKO group when compared to WT 
(Fig 3.7B).   
 
Figure 3.7. Expression of TIMPs. Total LV lysates (50 µg), prepared from sham and non
(NINF) and infarct (INF) LV regions, were analyzed by western blot using 
anti-TIMP-4 (B) antibodies. The upper panels show autoradiograms indicating immunostaining 
for TIMP-2, TIMP-4, and GAPDH. The lower panels exhibit quantitative analyses of TIMP
TIMP-4 normalized to GAPDH. *p<0.05 vs sham; 
 
Expression and phosphorylation of apoptosis
ATM phosphorylates p53 (serine
lysates using anti-p53 antibodies showed no immunostaining for p53 in the sham or non
LV regions of WT or hKO groups. Phosphorylation of p53 (seri
infarct regions with a greater increase in the hKO
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-4 protein levels were clearly present in 
-4 protein levels in the infarct LV region of both 
anti-
#p<0.05 vs NINF; $p<0.05 vs WT
-related proteins 
-15) following DNA damage [25]. Western blot analyses of LV 
ne-15) was only observed in the 
-MI group (Fig 3.8A).   
 
-infarct 
TIMP-2 (A) and 
-2, 
-INF; n=7. 
-infarct 
 Deficiency of ATM is suggested to associate with increased oxidative stress 
mitochondrial abnormalities are also reported in
analysis of mitochondrial antioxidant protein manganese superoxide dismutase (SOD
demonstrated no change in SOD
heart in both groups. MI significantly decreased SOD
groups. However, the decrease in SOD
WT (Fig 3.8B).  
 
Figure 3.8. Expression and phosphorylation of apoptosis
were analyzed by western blot using phospho
Protein loading in each lane is indicated by GAPDH immunostaining. $p<0.05 vs WT
B. Total LV lysates were analyzed by western blot 
in each lane is indicated by GAPDH. *p<0.05 vs sham; 
n=7. 
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-2 protein levels in the sham and non-infarct LV regions of the 
-2 protein levels in the infarct LV of both
-2 protein levels was significantly higher in hKO group vs 
-related proteins. A. Total LV lysates 
-specific (serine-15) p53 or total p53 antibodies. 
using anti-SOD-2 antibodies. Protein loading 
$p<0.05 vs NINF; #p<0.05 vs WT
[26]. Intrinsic 
]. Western blot 
-2) 
 
 
-INF; n=7. 
-INF; 
 Figure 3.9. Inhibition of ATM increases the number of ROS
apoptosis. ARVMs were treated 
stained using ROS-detection kit and ROS
microscopy. *p<0.05 vs control (CTL); n=3. B. TUNEL
apoptotic ARVMs. *p<0.05 vs CTL; n=3.  
 
Oxidative stress and apoptosis in ARVMs 
Inhibition of ATM using KU-55933 (KU) is shown to increase reactive oxygen species (ROS) in 
cancer cells [28]. To investigate if inhibition of ATM also increases ROS in myocytes, ARVMs 
were treated with KU (0.1 µM and 1 µM) for 3 h. Analysis of ROS
fluorescent microscopy showed increased number of ROS
concentrations of KU (Fig 9A). To investigate if inhibition of ATM induces apoptosis,  ARVMs 
were treated with KU (0.1 µM and 1 µM) for 24 h. Measurement of apoptosis using TUNEL
assay showed that KU at 0.1 µM and 1 µM concentrations significantly increases the number of 
apoptotic ARVMs (Fig 3.9B).  
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Discussion 
Previous studies from our lab have shown that lack of ATM induces structural and functional 
changes in the heart [10,11]. A major finding of this study is that deficiency of ATM attenuates 
LV dysfunction and dilatation 7 days post-MI. Although infarct size were comparable between 
the WT and hKO mice, infarct thickness was greater in the hKO mice. Deficiency of ATM 
associated with increased expression of α-SMA and fibrosis. Cardiac cell apoptosis was lower in 
the infarct LV region of ATM deficient mice. However, apoptosis was significantly higher in the 
border area of the infarct in ATM deficient mice. ATM deficiency also associated with changes 
in the expression of fibrosis- and apoptosis-related proteins. In vitro, inhibition of ATM 
increased the number of ROS-positive ARVMs and induced apoptosis. The results presented 
here suggest that ATM plays a multifaceted role in remodeling pathways following myocardial 
infarction.  
Systolic dysfunction is characterized by decreased cardiac contractility and pumping 
capacity of the heart. In general, MI results in severe LV dilation and systolic dysfunction [29].  
The data presented here demonstrate that ATM deficient mice suffer to a lesser degree from 
impaired systolic function following MI. The study also provides evidence that deficiency of 
ATM affects the infarct scar. We observed that the infarct size remained unchanged between WT 
and ATM deficient mice. However, infarct thickness was greater in the ATM deficient mice. 
Fibrosis and expression of α-SMA, a marker of myofibroblasts, was significantly higher in the 
ATM deficient heart after MI. Our findings suggest that myofibroblasts, a major cell type 
involved in the deposition of fibrosis, may escape the apoptotic death during the granulation 
phase and contribute to the increase in infarct wall thickness in the ATM deficient mice. This 
may in turn decrease LV dilation and dysfunction. Of note, cardiac cell apoptosis in the infarct 
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LV region of ATM deficient mice was lower when compared to that in the WT. Increased infarct 
thickness with reduced apoptosis in granulation tissue cells is previously described in 
Angiotensin II type 1A receptor KO (AT1AKO) 7 days post-MI [30]. Expression of soluble 
transforming growth factor-β (TGF-β) type II receptor, a competitive inhibitor of TGF-β, led to a 
greater infarct thickness and smaller LV circumference [31]. Therefore, it is conceivable that 
ATM signaling may involve Angiotensin II and/or TGF-β axis for its effect on infarct thickness, 
LV circumference and apoptosis. Further investigations are warranted to clarify the role of these 
molecules in ATM signaling. 
Cardiac structure consists of various cell types whose function is to promote contractility 
of the heart. Following injury, macrophages and other immune cells initiate a healing process. 
Once the damaged cells have been removed, activation of myofibroblasts helps promote scar 
tissue formation. This response is suggested to be associated with increases in α-SMA [21,32]. 
We observed greater increase in α-SMA expression in the infarct region of ATM deficient mice. 
Increased α-SMA may help explain the presence of increased fibrosis in the infarct region of 
ATM deficient mice.  
Cardiac cell apoptosis increases in the infarct and border  areas  and  to  a  smaller  extent  
in  the  non-infarcted areas of the heart after MI [6,33]. Early activation of apoptosis is a 
necessary step in remodeling as it allows room for entry of immune repair cells following injury 
[1,34,35].  The infarct region is a predictor of post-MI prognosis as it can relate to infarct 
expansion. ATM deficient mice exhibited a greater increase in apoptosis in the border region. 
This may lead to a greater infarct expansion and worse prognosis late post-MI [1,3,36]. 
Likewise, increased granulation tissue cell apoptosis in WT-MI hearts may reflect timely 
removal of unhealthy cells, thereby enhancing the repair process.  
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The matrix metalloproteinases (MMPs) are endopeptidases that are present within the 
myocardium. Changes in MMP abundance is shown to be associated with changes in 
extracellular matrix deposition (ECM) and LV remodeling post-MI, including increased LV 
dilation and cardiac rupture [37–41]. The ECM is a critical component in the restructuring of the 
heart after MI. Using promoter reporter constructs, Mukherjee et. al. showed that MMP-2 
promoter activation peaks in the MI region 7 days post-MI, while MMP-9 promoter activation 
was highest in the border region at 7 and 14 days post-MI [42]. Consistent with these findings, 
we observed increased MMP-2 protein levels in the MI regions of both groups when compared 
to their respective sham groups. No difference in MMP-2 protein levels and activity in the infarct 
LV region suggest that increased fibrosis in hKO mice occurs via MMP-2-independent 
mechanism. MMP-9 protein levels were significantly higher in the non-infarct LV region of WT 
group when compared to sham. However, we observed decreased MMP-9 protein levels in the 
infarct LV region of WT group. No such changes in MMP-9 protein levels were observed in the 
hKO group. MMP-9 activity was higher in the infarct LV region of hKO when compared to WT. 
Higher MMP-9 protein levels and activity suggest involvement of MMP-9 in ECM deposition 
and LV remodeling during ATM deficiency.  The decreased MMP-9 protein levels observed in 
this study in the WT infarct region may reflect localization and/or timing of the remodeling 
events.  [43]. Tao et al. has shown that MMP-9 activity increases as early as 1 day post-MI and 
reaches a maximum by 2 days, then gradually decreases. MMP-2 activity starts to increase 4 
days post-MI, reaching a maximum by 7 days [41].  
TIMP’s are traditionally believed to function solely as inhibitors of active MMPs [4]. 
TIMP-2 is suggested to have maximum affinity for MMP-2 [44]. In the heart, MMP-9 and 
TIMP-4 are suggested to play a key in the myocardial remodeling. In cardiac myocytes, the 
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effects of MMP-9 on voltage-induced contraction can be reversed by TIMP-4 [45]. We observed 
increased TIMP-2 expression in the infarct region of both groups to a similar extent. However, 
TIMP-4 protein levels were significantly lower in the ATM deficient mice. ATM deficient mice 
also exhibited increased MMP-9 protein levels and activity in the infarct region when compared 
to their WT counterparts. Increased MMP-9 activity is expected to correlate with decreased 
fibrosis in ATM deficient mice. However, we observed increased fibrosis in the infarct and 
remote regions of ATM deficient mice. Recent evidence suggests additional roles for TIMPs 
independent of their function as MMP inhibitors [36].  Therefore, it is plausible that changes in 
TIMP protein levels observed in the infarct region of WT and ATM deficient mice could 
function in the remodeling processes of the heart independent of MMP-2 and -9.   
ATM deficiency results in impaired repair of double-stranded DNA breaks and increased 
oxidative stress [26,46]. Deceased SOD levels impair the cell’s response to handle reactive 
oxygen species following myocardial injury [47,48]. ATM is also known to phosphorylate p53 
on serine-15 resulting in its stabilization. Stabilization of p53 increases its transcriptional 
activity, leading to increased apoptosis [49]. Here we observed greater increase in 
phosphorylation of p53 in the infarct region of ATM deficient hearts. On the other hand, SOD-2 
protein levels were lower in ATM deficient hearts, suggesting enhanced oxidative stress during 
ATM deficiency. Enhanced oxidative stress and apoptosis was also observed in ARVMs during 
inhibition of ATM using KU-55933. It can be argued that increased p53 phosphorylation and 
oxidative stress should increase apoptosis in the infarct region of ATM deficient mice. We did 
observe increased apoptosis in the border area of ATM deficient mice. However, apoptosis was 
lower in the infarct region of ATM deficient mice. Inhibition of ATM and ATR failed to prevent 
H2O2-induced phosphorylation of p53 in neonatal cardiac myocytes [50]. In addition, graded 
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increases in the level of oxidative stress induce a graded phenotype shift in cardiac myocytes, 
from hypertrophy at low levels of oxidative stress, to apoptosis at high levels of oxidative stress 
[51]. Therefore, it is conceivable that p53 phosphorylation during ATM deficiency involves 
signaling pathways independent of ATM, and increased oxidative stress during ATM deficiency 
promotes cell growth in the infarct LV region at this time point.   
Conclusion and study limitations  
The data presented here provide evidence that ATM has the potential to modulate infarct 
tissue dynamics. It alters the infarct structure by affecting apoptosis, fibrosis, and expression of 
α-SMA. It should be emphasized that our data on investigating the role of ATM in myocardial 
remodeling post-MI are obtained 7 days post-MI. Changes in the size and thickness of infarct 
scar can eventually affect infarct expansion and contribute to the diastolic dysfunction. 
Therefore, it is possible that increased fibrosis (stiffness) and apoptosis (in the border area) in 
ATM deficient mice may associate with earlier diastolic dysfunction if the study time points are 
extended beyond 7 days post-MI.  
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Abstract 
BACKGROUND: Ataxia telangiectasia mutated kinase (ATM) is a serine/threonine kinase that 
phosphorylates several proteins in response to cellular stressors such as DNA damage and 
oxidative stress.  We have previously shown that deficiency of ATM associates with increased 
apoptosis, increased fibrosis and attenuation of cardiac dysfunction 1, 3 and 7 days following 
myocardial infarction (MI). Here we investigated the role of ATM in cardiac remodeling 14 and 
28 days post-MI.  METHODS AND RESULTS: Left ventricle (LV) structure and function 
were measured in wild-type (WT) and ATM heterozygous knock (hKO) mice 14 and 28 days 
post-MI.  Biochemical parameters were measured 28 days post-MI.  MI resulted in cardiac 
dysfunction in both genotypes, as measured by a decrease in percent fractional shortening (%FS) 
and ejection fraction (EF). However, the decrease in %FS and EF was greater in the hKO-MI 
group versus the WT-MI group.  ATM deficiency had no effect on infarct size or infarct 
thickness.  However, the hKO group exhibited a tendency towards decreased survival post-MI.  
Fibrosis and expression of α-smooth muscle actin was greater in the hKO-MI infarct region, 
while apoptosis was greater in the WT-MI infarct region.  MI-induced increases in myocyte 
cross-sectional area were greater in the hKO-MI group versus the WT-MI.  Activation of 
glycogen synthase kinase-3β (GSK-3β) was significantly lower in the infarct region of the hKO-
MI group versus the WT-MI group.  Activation of extracellular signal-regulated kinases 
(ERK1/2) were significantly lower in the non-infarct region of the hKO-MI group versus WT-MI 
group. Expression of Beclin-1, a marker for autophagy, was greater in the hKO-sham as well as 
the non-infarct region of the hKO-MI.  Matrix metalloprotesase-2 (MMP-2) expression was not 
different between the two genotypes.  However, MMP-9 expression was significantly lower in 
the non-infarct region of the hKO-MI group versus the WT-MI group. The hKO-MI sham group 
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exhibited increased levels of cell senescence marker p16 when compared to the WT-sham group.  
However, the hKO-MI group exhibited decreased expression of p16 in the infarct region versus 
the WT-MI group.  CONCLUSION:  ATM deficiency worsened cardiac remodeling late post-
MI with increased cardiac dysfunction, fibrosis and myocyte hypertrophy.  It also associated 
with decreased cardiac cell apoptosis and senescence, which may have resulted in enhanced 
survival of myofibroblasts leading to increased fibrosis and cardiac dysfunction.  
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Introduction 
Following myocardial infarction (MI), the heart undergoes a remodeling process whereby the 
architecture and composition of the left ventricle (LV) changes. Factors affecting these changes 
include myocyte hypertrophy, myocyte apoptosis, myofibroblast proliferation and interstitial 
fibrosis (Konstam et al., 2011). During the early stages of LV repair, there is differentiation of 
fibroblasts into myofibroblasts.  The myofibroblast is a very proliferative cell type that secretes 
the majority of the collagen that ultimately forms the post-MI scar (Turner & Porter, 2013).  
Increases in autophagy can act as a source of ATP during the ischemia-induced energy shortage 
(Nishida et al., 2009).  The early changes in LV architecture include formation of a scar and 
thinning of the infarct region (Konstam et al., 2011).  During the later stages of cardiac 
remodeling, cross-linking of the newly formed scar occurs resulting in a reduction of 
myofibroblasts from the infarct region.  This reduction of myofibroblasts from the wound can 
occur as a result of apoptosis (Y Sun & Weber, 1996; Willems et al., 1994) and/or senescence.  
Senescence of myofibroblasts inhibits their ability to proliferate and also signals for their 
removal by natural killer (NK) cells.  However, mice deficient in p16, a regulator of senescence, 
exhibit increased fibrosis in the heart (Jun & Lau, 2010). The resulting scar is composed of the 
remaining myofibroblasts which continue to turn over type I and type III fibrillar collagen long 
after the scar has restored structural integrity to the infarcted myocardium (Yao Sun et al., 2002).  
MI-induced increases in autophagy during the later stages of remodeling often results in the 
accumulation of autophagosomes and is considered to be a contributing factor leading to 
myocyte death, hypertrophy and heart failure (Nishida et al., 2009). The later stages of structural 
remodeling are predominated by myocyte elongation in the non-infarcted zone, increased septal 
wall mass, chamber enlargement and a shift from an elliptical to a more spherical configuration 
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of the LV chamber. The changes in myocyte size as well as increases in interstitial fibrosis 
ultimately result in a progressive decline in ventricular performance eventually leading to heart 
failure (Konstam et al., 2011).  
 Ataxia telangiectasia mutated kinase (ATM) is activated in response to DNA damage.  
Following DNA damage, ATM phosphorylates several proteins involved in cell cycle arrest, 
DNA repair and apoptosis (Nowak-Wegrzyn, et al., 2004).  Mutations in the ATM gene cause 
the autosomal recessive disorder known as ataxia-telangiectasia (AT). AT individuals exhibit 
neuronal degeneration and are at increased risk for developing cancer (Taylor & Byrd, 2005). 
Carriers of only one mutated allele do not exhibit neuronal degeneration but are predisposed to 
cancer and ischemic heart disease, and die earlier than non-carriers as a result (Su & Swift, 
2000).  Previously, we examined the role of ATM in cardiac remodeling during the inflammatory 
and proliferative phases of the post-MI healing process.  ATM deficiency was shown to attenuate 
cardiac dysfunction.  In addition, ATM deficiency was associated with increased cardiac cell 
apoptosis and fibrosis post-MI (Daniel et al., 2014; Foster et al., 2013).  Although, early increase 
in fibrosis post-MI is suggested to help maintain heart function, it can ultimately result in cardiac 
dysfunction (See et al., 2013).  Apoptosis also associates with a negative post-MI outcome while 
inhibition of cardiac cell apoptosis is shown to reduce infarct size and preserve ventricular 
function (Holly et al., 1999; Rivard et al., 2007; Zhao et al., 2003). Here, we tested the 
hypothesis that enhanced fibrosis and apoptosis, as observed early post-MI during ATM 
deficiency, would result in greater cardiac dysfunction late post-MI in the ATM deficient group. 
These data presented here demonstrate that ATM deficiency exacerbates cardiac remodeling 28 
days post-MI with effects on LV function, fibrosis, apoptosis and myocyte hypertrophy.  ATM 
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deficiency also affected the expression and/or activation of proteins involved in apoptosis, 
fibrosis, hypertrophy, senescence and autophagy.   
Methods 
Vertebrate Animals:  
This investigation conforms to The Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The East 
Tennessee State University Animal Care and Use Committee approved all animal protocols. 
ATM transgenic mice (129xblack Swiss hybrid background) were originally purchased from 
Jackson Laboratory and created as previously described (Barlow et al., 1996). Aged-matched    
(~ 4-month-old) male and female mice were used for this study. ATM heterozygous knockout 
(hKO) mice were used in this study because homozygous (KO) mice die at approximately 2 
months of age, mainly due to thymic lymphomas (Barlow et al., 1996). Genotyping was 
performed by PCR using primers suggested by Jackson Laboratory. 
Myocardial infarction MI:  
MI was performed as previously described (Daniel et al., 2014). In brief, mice were anesthetized 
using 2% isoflurane inhalation and oxygen (0.5 L/min) and ventilated using a rodent ventilator. 
Body temperature was maintained at ~ 37ºC using a warmed platform. Hearts were exposed by a 
left thoracotomy followed by ligation of the left anterior descending artery (LAD) with a 7-0 
polypropylene suture. Mice in the sham group underwent the same procedure without ligation of 
the LAD. At the end of the study period (28 days) hearts were used for either histology or 
molecular analysis. 
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Echocardiography:  
Echocardiographic measurements were recorded 14 days and 28 days post-MI using a Toshiba 
Aplio 80 Imaging System (Tochigi, Japan) equipped with a 12 MHz linear transducer as 
previously described (Daniel et al., 2014). An individual blinded to the experimental groups 
recorded the images, while a second individual assessed the images and calculated the functional 
parameters of the heart. 
Morphometric analyses:  
Following MI, hearts were perfused with Krebs buffer and stopped in diastole using KCL (30 
mmol/L). Hearts were then fixed using 10% buffered formalin. Each heart was divided into 3 
transverse sections (base, mid and apex) and embedded in paraffin. Tissue sections were stained 
using Masson’s Trichrome stain in order to determine infarct size. Percent infarct size was 
determined by summing the midline infarct lengths of 3 histological sections and dividing them 
by the sum of the midline LV circumference and multiplying by 100 (Nascimento et al., 2011). 
Masson’s Trichrome-stained sections were also used to determine percent fibrosis. For this, 
images were obtained from at least five frames of the infarcted LV. Percent fibrosis was 
calculated by dividing total fibrosis by total tissue area and multiplying by 100. 
Terminal deoxynucleotidyl transferase nick end labeling (TUNEL) assay: 
TUNEL staining was carried out according to manufacturer’s instruction (Cell death detection 
assay; Roche). Sections (4 µm thick) were stained with Hoechst 33258 (Sigma) to identify nuclei 
and with rhodamine-conjugated wheat germ agglutinin (WGA) to identify myocytes. Apoptosis 
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was calculated as the total number of apoptotic cells divided by the total number of nuclei and 
multiplied by 100.   
Immunohistochemistry:  
Cross-sections of the heart (4 µm thick) were deparaffinized with xylene then rehydrated with 
graded ethanol rinses. Immunohistochemical staining for myofibroblasts was performed using 
anti-α-smooth muscle actin (α-sma) antibodies (Sigma). All images were acquired using a Nikon 
TE-2000 microscope with an Andor Zyla sCMOS camera. Quantitative analysis was carried out 
using Nikon’s NIS-Elements software.  
Myocyte Cross‐Sectional Area 
Cross‐sections of the heart (4 µm thick) were stained with rhodamine‐conjugated WGA to 
measure myocyte cross‐sectional area. Images were acquired using fluorescent microscopy and 
recorded using an Andor Zyla sCMOS camera. Suitable area of the section was defined as 
myocytes with nearly circular profiles. Myocyte cross‐sectional areas were measured using 
Nikon’s NIS-Elements software as described (Daniel et al., 2014).  
Western Blot Analysis:  
LV lysates were prepared in RIPA buffer, separated by SDS-PAGE and transferred to a PVDF 
membrane.  Following an initial blocking using either 5% non-fat milk or 2% BSA in TBST, the 
membranes were then incubated overnight with antibodies against p16, Beclin-1, MMP-2, MMP-
9 (Santa Cruz), p-GSK-3β (Ser9) and p-ERK1/2 (Thr202, Tyr204) (Cell Signaling). GAPDH 
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(Santa Cruz) immunostaining was used as a protein loading control. Band intensities were 
quantified using Kodak photo documentation system.  
Statistical Analyses:  
Data are represented as mean ± SEM. Data were tested for normality using a Shapiro-Wilk test. 
Multiple comparisons were analyzed using either one-way ANOVA or a Kruskal-Wallis test.  
All pairwise comparisons were carried out using either a one-tailed student’s t-test or a Mann-
Whitney U-test. Survival analysis was performed using log rank test. Probability (P) values of 
<0.05 were considered to be significant. 
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Results 
Survival and Morphological Analyses 
There was no significant difference in infarct size (% infarct-size; WT 38.8 ± 3.5; hKO 38.0 ± 
3.8; p = ns; n = 7- 9) or infarct width (WT 48.9 ± 11.1 µm; hKO 43.2 ± 4.1 µm; p = ns; n = 7- 9) 
between the two groups 28 days post-MI.  The survival rate between the two genotypes was not 
different 1-7 days post-MI.  At 7 days post-MI survival in WT and hKO group was 55.2% (WT, 
37/67) and 52.9% (hKO, 37/70), respectively.  Interestingly, Kaplan-Meier analysis showed 
survival rates of 52.2% in the WT-MI and 40.0% in hKO 28 days post-MI (Fig 4.1; p=0.228).  
 
Figure 4.1. Kaplan Meyer survival curve. WT, wild-type mice; hKO heterozygous knockout 
mice 
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There was no significant difference in the body weight (BW) between the two genotypes. 
Both MI groups had a significant increase in heart weight (HW) and HW/BW ratio when 
compared to their respective sham groups, with no significant difference between the two 
genotypes (Table 4.1).  
Table 4.1.  Morphometric Measurements 28 Days Post-MI 
Values are mean ±SEM; #P<0.05 vs sham. WT, wild-type; hKO, heterozygous; MI, myocardial 
infarction 
 
Echocardiographic studies 
There was no significant difference in ejection fraction (EF) between the two sham 
groups.  However, the WT-sham group exhibited slightly higher percent fractional shortening 
(%FS) when compared with the hKO-sham group. Percent FS and EF decreased in both MI 
groups when compared to their respective sham group 14 and 28 days post-MI.  Interestingly, the 
decrease in %FS and EF was significantly greater in the hKO-MI group when compared to the 
WT-MI group at both time points (Fig 4.2).  
 Body Weight Heart Weight HW/BW 
WT-Sham (N=8) 25.89 ± 0.60 107.66 ± 3.21 4.16 ± 0.05 
hKO-Sham (N=9) 28.90 ± 1.57 119.29 ± 13.68 4.57 ± 0.21 
WT-MI (N=21) 25.36 ± 0.73 158.27 ± 9.90 # 6.67 ± 0.46 # 
hKO-MI (N=22) 26.03 ± 0.67 158.92 ± 6.00 # 6.13 ± 0.20 # 
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Figure 4.2. ATM deficiency worsens LV function post-MI. A. M‐mode echocardiographic 
images. B. Indices of cardiac function percent fractional shortening (%FS) and ejection fraction 
(EF) were calculated using echocardiographic images 14 and 28 days post‐MI. #P<0.001 vs 
Sham, *P<0.05 vs WT; n=7-11.  
 
 Quantitative measurement of fibrosis using Mason’s Trichrome-stained sections showed 
that the hKO-sham group exhibited increased fibrosis in the infarct region when compared to the 
WT-sham group.  At 28 days post-MI, there was a significant increase in fibrosis in the non-
infarct and infarct region of both genotypes when compared to their respective sham groups. 
However, the increased infarct fibrosis was significantly greater in the hKO-MI group when 
compared to the WT-MI group.  There was no significant difference in fibrosis in the non-infarct 
region between the two genotypes (Fig 4.3). 
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Figure 4.3. ATM deficiency results in increased fibrosis. The upper panels depict Masson's 
trichrome‐stained heart sections of WT and hKO (sham and infarct region 28 days post-MI). 
Lower panel exhibits quantitative analysis of fibrosis. #P<0.05 vs Sham, $P<0.05 vs non-infarct; 
*P<0.05 vs WT‐MI; n=6-8. Non, non-infarct; Inf, infarct. 
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There was no significant difference in the total cardiac cell apoptosis between the two 
sham groups. Apoptosis was significantly higher in the non-infarct and infarct regions of both 
genotypes at 28 days post-MI when compared to their respective sham groups. There was no 
significant difference in apoptosis between the two genotypes in the non-infarct region.  
However, apoptosis was significantly higher in the infarct region of the WT-MI group when 
compared to the hKO-MI group (Fig 4.4).  Myocyte apoptosis was not significantly different 
between the two genotypes in the sham groups or in the non-infarct regions (data not shown).  
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Figure 4.4. ATM deficiency decreases apoptosis in the infarct region 28 days post-MI. Upper 
panels depict TUNEL‐stained (left) and Hoechst‐stained (right) images obtained from WT (top) 
and hKO (bottom) hearts post‐MI. Green fluorescent staining indicates TUNEL‐positive 
(apoptotic) nuclei, while blue fluorescent staining indicates total number of nuclei. The lower 
panel exhibits quantitative analysis. #P<0.05 vs Sham, *P<0.05 vs WT, $P<0.05 vs Non; n=5-8.  
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Myocyte cross-sectional area was greater in the hKO-sham group when compared to the 
WT-sham group.  Following MI, there was a significant increase in myocyte cross-sectional area 
in both genotypes when compared to their respective sham groups. However, myocyte cross-
sectional area in the non-infarct region was significantly larger in the hKO-MI group when 
compared to the WT-MI group (Fig 4.5).  
 
Figure 4.5. ATM deficiency increases myocyte cross-sectional area. Cross‐sections of the heart 
were stained using rhodamine-conjugated anti‐WGA. Upper panels depicts WGA‐stained images 
from the sham (top) and the non-infarct regions (bottom) of WT (left) and hKO (right) hearts 
post‐MI. Lower panel exhibits quantitative analysis of myocyte cross-sectional areas in the sham 
and the non-infarct regions 28 days post‐MI. #P<0.001 vs Sham, *P<0.05 vs WT; n=7-8.  
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Expression of α-Smooth Muscle Actin (α-sma) 
Myofibroblasts are the main producers of collagen post-MI.  Expression of α-sma is 
commonly used to identify myofibroblasts (Eddy, Petro, & Tomasek, 1988).  There was no 
significant difference in α-sma expression between the two sham groups. Twenty-eight days 
post-MI, α-sma expression was significantly greater in the infarct region of both genotypes when 
compared to their respective sham groups or their non-infarct regions. However, α-sma 
expression was significantly higher in the infarct region of the hKO-MI group versus the WT-MI 
group (Fig 4.6).  
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Figure 4.6. ATM deficiency increases α‐sma expression 28 days post-MI. Cross‐sections of the 
hearts were immunostained using anti‐α‐sma antibodies. Upper panel depicts α‐sma‐stained 
images from the infarct regions of WT and hKO hearts 28 days post‐MI. Lower panel exhibits 
quantitative Immunohistochemical analysis of α‐sma expression. #P<0.01 vs Sham, $P<0.01 vs 
Non-infarct, *P<0.05 vs WT; n=6-7. 
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Phosphorylation of GSK-3β and ERK1/2. 
Glycogen synthase kinase-3β (GSK-3β) is a pro-apoptotic kinase that is inactivated by 
phosphorylation at serine-9 (Sutherland et al., 1993).  This inactivation of GSK-3β by 
phosphorylation remained unchanged between the sham groups and non-infarct regions of the 
two groups 28 days post-MI.  However, GSK-3β phosphorylation was significantly lower in the 
infarct region of the WT-MI group when compared to the infarct region of the hKO-MI, 
suggesting enhanced activation of GSK-3β in the WT-MI groups (Fig 4.7A).  
 
 
Figure 4.7. ATM deficiency decreases GSK‐3β and ERK1/2 activities 28 days post-MI. Total LV 
lysates, prepared from sham and non-infarct and infarct LV regions post‐MI, were analyzed by 
western blot using phospho‐specific antibodies for GSK‐3β (Ser9) and ERK1/2 (Thr202, 
Tyr204). The upper panels depict autoradiograms immunostained for p‐GSK‐3β, p-ERK1/2 and 
GAPDH. The lower panels exhibit quantitative analyses of p‐GSK‐3β (n=8) and p-ERK1/2 (n=8) 
normalized to GAPDH.*P<0.05 vs WT‐Inf.  
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Activation of ERK1/2 plays a role in cell proliferation, differentiation, apoptosis and 
cardiac hypertrophy (Bueno et al., 2000; Lin et al., 2013). ERK1/2 phosphorylation (activation) 
remained unchanged between the sham groups. At twenty-eight days post-MI, there was a 
significant increase in ERK1/2 activation in the infarct region of both genotypes with no 
difference between the two genotypes.  However, phosphorylation of ERK1/2 was significantly 
lower in the non-infarct region of the hKO-MI group when compared to the WT-MI group 
(Figure 4.7B).  
Expression of Beclin-1 and p16  
Increased Beclin-1 expression associates with increased autophagy.  Mice deficient in Beclin-1 
exhibit decreased autophagy and attenuated pathological remodeling following myocardial 
ischemia/reperfusion injury and aortic banding (Matsui et al., 2007; Zhu et al., 2007).  Beclin-1 
protein levels were significantly higher in the hKO-sham group when compared to the WT-sham 
group.  Following MI, Beclin-1 protein levels stayed higher in the non-infarct region of the hKO-
MI group when compared to the WT-MI group (Figure 4.8). However, no significant difference 
in Beclin-1 expression was observed in the infarct region between the two genotypes. 
119 
 
 
Figure 4.8. ATM deficiency increases expression of Beclin-1. Total LV lysates, prepared from 
the sham and non‐infarct and infarct LV regions 28 days post‐MI, were analyzed by western blot 
using anti‐Beclin-1 antibodies. The upper panels depict autoradiograms immunostained for 
Beclin-1 and GAPDH. The lower panels exhibit quantitative analyses of Beclin-1 normalized to 
GAPDH. *P<0.05 vs WT; n=6-8. 
 
The protein p16 is expressed by most senescent cells (Rodier & Campisi, 2011).  
Expression of p16 was higher in the hKO-sham group when compared to the WT-sham group.  
Following MI, no significant difference in p16 protein levels was observed between the two 
genotypes in the non-infarct regions.  However, the infarct region of the hKO-MI group 
exhibited decreased protein levels of p16 when compared to the WT-MI group (Fig 4.9). 
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Figure 4.9. ATM deficiency alters p16 expression. Total LV lysates, prepared from sham and 
non‐infarct and infarct LV regions 28 days post‐MI, were analyzed by western blot using 
anti‐p16 antibodies. The upper panels depict autoradiograms immunostained for p16 and 
GAPDH. The lower panels exhibit quantitative analyses of p16 normalized to GAPDH. *P<0.05 
vs WT; n=6-7. 
 
Expression of MMP-2 and MMP-9.  
Matrix metalloproteinases (MMP-2 and -9) play an important role in the fibrotic response 
following MI (Lindsey & Zamilpa, 2012).  MMP-2 expression and activity increase in the infarct 
region following MI peaking 7 days post-MI and decreasing thereafter.  MMP-9 is activated 
following MI and its activity remains elevated until 14 days post-MI (Cleutjens et al., 1995). 
MMP-2 expression was significantly lower in the infarct region of both MI groups when 
compared to their respective sham group with no significant differences in MMP-2 expression 
between the two genotypes (data not shown). There was a significant decrease in MMP-9 
expression in the infarct region of both genotypes when compared to their respective sham 
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groups.  However, no significant differences were observed between the two genotypes in either 
the sham group or the infarct region.  Interestingly, MMP-9 protein levels were significantly 
lower in the non-infarct region of the hKO-MI group when compared to that of the WT-MI 
group (Figure 10). 
 
Figure 4.10. ATM deficiency decreases expression of MMP-9 in the non-infarct region 28 days 
post-MI. Total LV lysates, prepared from sham and non‐infarct and infarct LV regions 28 days 
post‐MI, were analyzed by western blot using anti‐MMP-9 antibodies. The upper panels depict 
autoradiograms immunostained for MMP-9 and GAPDH. The lower panels exhibit quantitative 
analyses of MMP-9 normalized to GAPDH. *P<0.05 vs WT; n=8. 
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Discussion 
The data presented here demonstrate that ATM deficiency associates with LV dysfunction, 
increased expression of p16 and Beclin-1, increased myocyte cross-sectional area and increased 
fibrosis in the sham group. Twenty-eight days post-MI, ATM deficiency associated with a 
greater decline in LV function.  Post-MI survival tended to be lower in the ATM deficient group. 
Myocardial fibrosis and expression of α-sma was higher in the ATM deficient group, while 
apoptosis was higher in the WT group 28 days post-MI.    Myocyte cross-sectional area was 
greater in the ATM deficient group.  Beclin-1 expression remained higher in the hKO-MI group 
when compared to the WT-group, but only in the non-infarcted region.    ATM deficiency 
associated with lower activity of ERK1/2 in the non-infarct region and lower GSK-3β activity in 
the infarct region.   It was also associated with lower p16 expression in the infarct region.  ATM 
deficiency associated with lower MMP-9 expression in the non-infarct region.  Thus, ATM 
deficiency affects heart function and molecular parameters of the heart associated with apoptosis, 
fibrosis, autophagy and senescence 28 days post-MI. 
In the sham group, ATM deficiency associated with reduced cardiac function, increased 
fibrosis and myocyte hypertrophy.  ATM deficiency also associated with increased expression of 
p16 and Beclin-1.  p16 is a marker for cellular senescence and has been shown to be elevated in 
the myocytes of aged diseased hearts.  The presence of p16 is also associated with myocyte 
hypertrophy and myocyte apoptosis (Chimenti et al., 2003; Nadal-Ginard, 2003; Urbanek et al., 
2003).    The aged heart is shown to exhibit increased expression of the autophagy-related 
protein, Beclin-1 (Wohlgemuth et al., 2007) as well as increased cardiac fibrosis (Shinmura et 
al., 2011).  Therefore, the observation of increased fibrosis, myocyte hypertrophy and increased 
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expression of p16 and Beclin-1 suggest that ATM deficiency may result in the premature aging 
of the heart. 
Fourteen and 28 days post-MI, ATM deficiency associated with exacerbated cardiac 
dysfunction as determined by decreased %FS and EF.  Cardiac fibrosis following MI occurs 
primarily as a result of collagen secretion by myofibroblasts (Turner & Porter, 2013).  Inhibition 
of myofibroblast apoptosis has been linked to the progression of cardiac fibrosis (Li et al., 2004).  
An increase in cardiac fibrosis following MI has been suggested to cause cardiac dysfunction 
(See et al., 2013).    Here, we observed decreased apoptosis, increased fibrosis and increased 
expression of α-sma in the infarct region of ATM deficient hearts.  Although not indentified 
here, we speculate that the observed decrease in apoptosis in the infarct region during ATM 
deficiency is due to the decrease in myofibroblast apoptosis.  It is interesting to note that 
myofibroblasts are identified as the major cell type undergoing apoptosis in the infarct region at 
this time point (W. Zhao, Lu, Chen, & Sun, 2004).  This increase in fibrosis may be a 
contributing factor towards the observed LV dysfunction during ATM deficiency 28 days post-
MI.   
ATM deficiency also associated with increased expression of Beclin-1, an autophagy-
related protein, in the non-infarct region following MI. During energy deprivation, such as an 
ischemic event, a cell uses autophagy to generate ATP.  This is done by degrading cytosolic 
proteins and organelles (Levine & Kroemer, 2008).  In this regard, increased autophagy can be 
beneficial following MI (Kanamori et al., 2011).  However, when autophagy levels are too high, 
the volume occupied by the autophagic vacuoles can become too large leading to apoptosis 
(Maiuri, Zalckvar, Kimchi, & Kroemer, 2007).  Of note, Beclin-1+/- mice exhibit a reduction in 
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autophagosome formation and a reduction in infarct size following myocardial 
ischemia/reperfusion injury (Matsui et al., 2007).  Lack of ATM results in mitochondrial 
dysfunction in thymocytes in vivo.   However, allelic loss of Beclin-1 in these mice attenuated 
these abnormalities (Valentin-Vega et al., 2012).  Thus, increased expression of Beclin-1 is 
likely deleterious during ATM deficiency.  This may provide another explanation as to why 
ATM deficiency presents itself with exaggerated cardiac dysfunction 14 and 28 days post-MI. 
ATM deficiency also associated with increased myocyte cross-sectional area.  Cardiac 
hypertrophy is induced following myocardial infarction in order to maintain cardiac output 
during myocyte loss (Gould et al., 2002).  However, increases in myocyte size can often result in 
cardiac dysfunction late post-MI (Konstam et al., 2011).  This increased myocyte size could be a 
contributing factor to the increased cardiac dysfunction in ATM deficient mice.  Induction of 
hypertrophic signaling often converges on MAPK signaling pathway, which includes ERK1/2, 
Jun N-terminal kinase (JNK) and p38 (Wakatsuki, Schlessinger, & Elson, 2004).  Activation of 
ERK1/2 is shown to induce cardiac hypertrophy.  However, this induction is thought to be 
compensatory, not pathological, as is the case during the later stages of post-MI infarct healing.  
Similar pathways that are involved in ERK1/2 activation also activate JNK. Recent work using 
JNK transgenic mice suggest an anti-hypertrophic role for JNK (reviewed in (Liang, 2003)).  
Activation of ERK1/2 is reduced in the non-infarct region of the hKO-MI group, which suggests 
that ERK1/2 is not likely involved in the modulation of myocyte size at this time point.  
Previously, our lab has shown that β-AR stimulation activates JNK in WT mice but not in ATM 
KO mice (Foster, Singh, Subramanian, & Singh, 2011).  Therefore, the increased hypertrophic 
response observed during ATM deficiency may in part be due to alterations in the activity of 
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JNK.  Alternatively, the increased expression of Beclin-1 may result in increased hypertrophy 
via the accumulation of autophagic vesicles. 
Activation of ERK1/2 is also shown to result in an increased fibroblast proliferation 
(Bueno et al., 2000; Lin et al., 2013).  However, there was no difference in ERK1/2 activation 
between the two genotypes in the infarct region. This suggests that the increase in expression of 
α-sma during ATM deficiency occurs independently of ERK1/2 pathway.  However, the increase 
in fibrosis during ATM deficiency could be a result of decreased GSK-3β activity and/or 
increased expression of p16, both of which can lead to increased cell proliferation.  
Changes in MMP expression can result in changes in fibrosis (Matsui, Morimoto, & 
Uede, 2010).  There was no difference in MMP-2 expression between the two genotypes. ATM 
deficiency associated with a reduction in MMP-9 expression in the non-infarct region. However, 
there were no differences in fibrosis between the two genotypes in the non-infarct region.  
Differences in fibrosis were only observed in the infarct region.  These data suggest that changes 
in MMP-9 expression may not be a major contributing factor toward fibrosis late post-MI.  
This study is a continuation of a project in which we examined how ATM deficiency 
affected cardiac remodeling during the inflammatory phase of infarct healing (1 and 3 days post-
MI) and during the proliferative phase of healing (7 days post-MI) (Daniel et al., 2014; Foster et 
al., 2013). An important finding of those studies was that early post-MI infarct healing appeared 
to benefit from ATM deficiency in terms of cardiac function.  However, this deficiency 
ultimately had negative consequences on cardiac function, which might be attributed to increased 
cardiac fibrosis as well as increased myocyte apoptosis.  At this time, future investigations are 
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needed to clarify the role of ATM in cell survival and growth in different cell types of the heart 
post-MI. 
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CHAPTER 5 
CONCLUSION  
Carriers of ATM exhibit enhanced susceptibility towards ischemic heart disease. Here, 
we observed that MI increased expression of ATM in the infarct and non-infarct LV regions of 
the heart. Using ATM deficient mice, this study investigated the role of ATM in different phases 
of infarct healing post-MI.  A major finding of this study was that ATM modulated cardiac 
structure and function post-MI by affecting myocardial fibrosis, apoptosis and myocyte 
hypertrophy.  Early post-MI (1, 3 and 7 days), ATM deficiency associated with increased 
fibrosis which correlated with attenuated dilative remodeling and cardiac dysfunction.  However, 
late post-MI (14 and 28 days post-MI), ATM deficiency associated with greater cardiac 
dysfunction which we attributed to increased myocardial fibrosis and myocyte hypertrophy. At 
each stage of infarct healing, there is a different cell type predominately undergoing apoptosis. 
Early post-MI, the predominant cell type undergoing apoptosis is myocytes. After the majority of 
myocytes have been lost from the infarct region, inflammatory cells become the predominant cell 
type undergoing apoptosis. During the last stages of infarct healing, myofibroblasts become the 
primary cell type undergoing apoptosis in the infarct region.  On the other hand, the primary cell 
type undergoing apoptosis, during the later stages of remodeling, in the non-infarct region is 
myocytes (Zhao et al. 2004).  The data presented here suggest that ATM deficiency increased the 
susceptibility of myocytes towards apoptosis, while decreasing the susceptibility of fibroblasts 
towards apoptosis.   
ATM and Inflammatory Phase 
During the inflammatory phase of post-MI healing (1 and 3 days post-MI) ATM 
deficiency delayed the inflammatory response post-MI and resulted in decreased dilative 
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remodeling. In the infarct region, ATM deficiency resulted in enhanced fibrosis and expression 
of α‐sma (myofibroblast marker). However, cardiac cell apoptosis was higher during ATM 
deficiency. Activation of the anti-apoptotic kinase Akt and inactivation of pro-apoptotic kinase 
GSK-3β were lower, while the expression of the pro-apoptotic protein Bax was higher in the 
infarct region during ATM deficiency.   
MI causes cardiac cell death via necrosis and apoptosis. Necrosis leads to inflammatory 
response via the release of chemokines which attract neutrophils. Leukocytes extravasation 
primarily occurs in post-capillary venules (Ma et al. 2013). The retina of mice lacking ATM is 
shown to have decreased vasculature when compared to the retina of WT mice (Raz-Prag et al. 
2011).  Although not investigated here, the reduced inflammatory response observed during 
ATM deficiency could be, at least in part, due to decreased vasculature in the heart. Increased 
apoptosis can also affect the inflammatory response post-MI.  Apoptotic cells release signals 
such as lactoferrin and annexin 1 which can inhibit neutrophil recruitment (Hayhoe et al. 2006; 
Bournazou et al. 2009). Therefore, increased apoptosis during ATM deficiency post-MI can 
cause inhibitory effects on neutrophil migration.  
Cardiac cell death following MI leads to an increase in wall stress resulting in dilative 
remodeling and decreased survival post-MI.  However, an early increase in collagen fibers can 
prevent dilative remodeling (White et al. 1987; Sutton and Sharpe 2000).  Here, we observed 
decreased dilative remodeling and increased fibrosis during ATM deficiency post-MI. Therefore, 
increased fibrosis may contribute to the decreased dilative remodeling during ATM deficiency 
post-MI.  Myofibroblasts are the main producers of collagen in the infarct region.  The collagen 
being produced in the non-infarcted region originates from undifferentiated fibroblasts 
(Cleutjens, Verluyten, et al. 1995).  In the uninjured heart fibroblasts are inactive. Following MI, 
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fibroblasts experience mechanical stress due to myocyte death, resulting in their activation and 
differentiation into myofibroblasts (Li et al. 1997; Turner and Porter 2013).  The differentiation 
of fibroblast is also aided by biochemical stimuli, such as TGF-β1 and fibronectin splice form 
ED-A (Turner and Porter 2013).  TGF-β1 is secreted as a latent protein and associates with the 
latency-associated peptide (LAP).  It remains inactive until it is activated by either proteolytic 
cleavage or mechanical force (Buscemi et al. 2011).  Three days post-MI, ATM deficiency 
resulted in higher expression of α-sma and fibrosis.  However, levels of active TGF-β1 were 
lower in the infarct region during ATM deficiency. These data suggest that activation of TGF-β1 
may not be solely responsible for differentiation of fibroblasts into myofibroblasts during ATM 
deficiency. Increased mechanical stress and/or ED-A splice variant of fibronectin may play a role 
in fibroblast differentiation during ATM deficiency.   
ATM deficiency associated with increased apoptosis 1 and 3 days post-MI when 
compared to WT.  During this time point, myocytes and inflammatory cells are the predominant 
cell types undergoing apoptosis (Zhao et al. 2004).  Therefore, the increased apoptosis could be 
attributed to either one of these two cell types. Activation of Akt plays an anti-apoptotic role in 
cardiac myocytes, in part by acting upstream in the phosphorylation and inactivation GSK-3β 
(Sutherland et al. 1993).  Akt has also been shown to inhibit Bax (a pro-apoptotic protein) by 
phosphorylating it on Ser-184 (Gardai et al. 2004).  One day post-MI, ATM deficiency 
associated with decreased activation of Akt and an enhanced activation of GSK-3β.  Also, 
expression of Bax was higher in the infarct region 3 days post-MI during ATM deficiency. 
Therefore, enhanced apoptosis, early post-MI, in the infarct region appears to be due to 
decreased survival signaling during ATM deficiency.    
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ATM and the Proliferative Phase 
Seven days post-MI, ATM deficiency associated with attenuation of cardiac dysfunction 
and dilative remodeling as well as increased infarct thickness, fibrosis and expression of α-sma. 
ATM deficient mice exhibited lower total cardiac cell apoptosis in the infarct region.  The two 
main cell types undergoing apoptosis at this time point, in the infarct region, are macrophages 
and myofibroblasts.  ATM deficiency associated with enhanced expression of α-sma and fibrosis 
in the infarct region post-MI. Therefore, it can be argued that the decreased apoptosis in the 
infarct region during ATM deficiency may be due to decreased myofibroblast apoptosis. The 
increased fibrosis may have contributed to the increased infarct wall thickness leading to 
decreased LV dilation and dysfunction.  
Another interesting finding of this study was that ATM deficient mice exhibited 
increased myocyte apoptosis in the border region, when compared to WT. Increased myocyte 
apoptosis in the border region is predicative of infarct expansion, resulting in a worse outcome 
late post-MI (Frantz et al. 2009; Kempf et al. 2012).  Therefore, it is possible that increased 
fibrosis and apoptosis in the border region during ATM deficiency may associate with cardiac 
dysfunction if the study time points are extended beyond 7 days post-MI. Although there was 
higher myocyte apoptosis in the border area during ATM deficiency, the attenuated cardiac 
dysfunction as well as the increased infarct thickness might be attributed to increased infarct 
fibrosis.  
ATM and the Maturation Phase 
Fourteen and 28 days post-MI, ATM deficient mice exhibited greater cardiac 
dysfunction.  We also saw a trend towards enhanced mortality in ATM deficient mice 28 days 
post-MI.  Fibrosis and expression of α-sma in the infarct region remained higher in ATM 
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deficient mice 28 days post-MI.  Therefore, it appears that the increased fibrosis during ATM 
deficiency only delays dilative remodeling resulting in an initial attenuation of cardiac 
dysfunction.  Cross-linking of the collagen matrix, which occurs during the maturation phase of 
cardiac remodeling, leads to increases in passive stiffness resulting in cardiac dysfunction (Kato 
et al. 1995; Badenhorst et al. 2003).  The increased fibrosis during ATM deficiency could be 
contributing to exacerbated cardiac dysfunction 14 and 28 days post-MI.  
ATM deficiency associated with decreased apoptosis in the infarct region.  At this time 
point, the majority of cells undergoing apoptosis are most likely myofibroblasts. In addition, 
expression of α-sma was higher in ATM deficient hearts, supporting our hypothesis that ATM 
deficiency may be anti-apoptotic for myofibroblasts.  Levels of active GSK-3β were lower in the 
infarct region of ATM deficient hearts. Active GSK-3β can inhibit cell cycle and lead to 
apoptosis (Alt et al. 2000; Hall et al. 2001; Antos et al. 2002). Therefore, decreased GSK-3β 
activity during ATM deficiency could have contributed to not only decreased myofibroblast 
apoptosis, but also to increased myofibroblast proliferation. Induction of senescence in 
myofibroblasts is an important step to inhibit fibrosis (Jun and Lau 2010). In streptozotocin-
induced model of diabetes, ATM deficiency is shown to inhibit endothelial senescence (Zhan et 
al. 2010).  Here, we observed decreased expression of p16 in the infarct region of ATM deficient 
hearts.  Therefore, decreased myofibroblast senescence may also explain increased expression of 
α-sma in the infarct region during ATM deficiency.  Of note, expression of p16 was higher in 
ATM deficient sham hearts.  Expression of Beclin-1, an autophagy-related protein, was also 
higher in ATM deficient sham hearts. Expression of autophagy-related proteins is shown to be 
impaired in the aged heart (Wohlgemuth et al. 2007). The increased expression of p16 and 
138 
 
Beclin-1 during ATM deficiency points toward premature aging of the myocytes and possible 
predisposition to myocyte apoptosis post-MI.   
Future Directions  
Future directions of the study are numerous. We showed that MI increases the expression 
of the ATM gene in the heart in both the infarct and non-infarct LV regions. Therefore, it would 
be interesting to identify the cell-type involved in the increased expression of ATM post-MI.   
Mitogenic signals have also been shown to increase expression of ATM in peripheral blood 
mononuclear cells (Fukao et al. 1999). In addition ,we have previously shown, that β-AR 
stimulation increased ATM expression in the heart and in cardiac myocytes (Foster et al. 2011).  
In certain neuronal cell types, expression of ATM is shown to decrease when the cell 
differentiates into a non-dividing phenotype, at which point ATM moves from the nucleus into 
the cytoplasm.  Here it can play an anti-apoptotic role, protecting the cell from serum starvation 
(Allen et al. 2001; Boehrs et al. 2007). Therefore, it is possible that a differential expression of 
ATM and/or differential cellular localization of ATM may influence the apoptotic response 
differently in myocytes versus fibroblasts. However, further investigations are needed to identify 
factors and cell types involved in the increased ATM expression in the heart post-MI. 
The data presented here suggest that ATM deficiency decreased heart function and 
worsened survival late post-MI. As discussed, different phases of the infarct healing process 
involve different cell types of the heart undergoing apoptosis. Previous work from our lab 
showed cardiac myocyte apoptosis and myocardial fibrosis was greater in the myocardium of 
ATM deficient mice 28 days following β-AR stimulation (Foster et al. 2011).  The previous 
study in combination with the work presented here leads us to hypothesize that ATM deficiency 
predisposes cardiac myocytes to apoptosis while either protecting myofibroblasts against 
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apoptosis and/or resulting in increased proliferation of the myofibroblasts. A major limitation of 
this study is that we did not identify the cell types undergoing apoptosis. Identification of the cell 
types undergoing apoptosis may help explain the healing process of the heart during ATM 
deficiency. Post-MI healing is a complex process involving various cytokines, chemokines and 
growth factors. Signals such as lactoferrin and annexin 1 can inhibit recruitment of neutrophils to 
the injury site. Chemokines and cytokines present at different phases of infarct healing can 
influence the fibrotic and apoptotic response. Future investigations are needed to determine if 
ATM deficiency influences the production of cytokines, chemokines and growth factors in the 
heart post-MI.    
Another interesting observation is that the increased fibrosis during ATM deficiency only 
delayed dilative remodeling resulting in an initial attenuation of cardiac dysfunction. However, 
increased fibrosis may have ultimately led to exacerbated heart dysfunction late post-MI. 
Deposition of fibrotic tissue is a complex process involving synthesis and degradation of ECM 
that relies on various MMPs and TIMPs. The current study mainly investigated the protein levels 
of MMP-2 and -9. A thorough analysis of different components leading to fibrosis may provide 
insight into the modulation of heart function during ATM deficiency post-MI.  
Likewise, apoptosis is complex process involving a variety of signaling molecules. Using 
mice lacking ATM and acute β-AR stimulation as a model, we have previously provided 
evidence that the signaling pathway involved in myocyte apoptosis was different in the presence 
or absence of ATM.  In WT hearts, β-AR-stimulated apoptosis occurred via the involvement of 
p53 and JNKs pathway. However, decreased Akt activity may have played a role in β-AR-
stimulated myocyte apoptosis in the absence of ATM (Foster et al. 2012).  The study done here 
points towards the involvement of ATM in cell senescence and autophagy. Future investigations 
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are required to understand the signaling mechanism and organelles involved in this process and 
whether the changes in these mechanisms are beneficial or detrimental.   
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